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1. Introduction - 1 -
1. Introduction 
 
Cardiovascular diseases are the major cause of death and morbidity in adults in most 
developed and many developing countries. In Germany, according to the statistics in 2004, 
23.7 % of all deaths were caused by cardiovascular diseases, in particular by chronic ischemic 
heart disease, acute myocardial infarction and heart failure 1. In the same year, 32,241 patients 
died of stroke which represents the 5th most frequent cause of death. In Germany, 30 % of the 
sixty year and older population suffers from peripheral arterial occlusive disease. The main 
causes of death of these patients are myocardium infarction, heart failure and sudden cardiac 
death 2. Up to date, treatment involves percutaneous revascularisation with balloon 
angioplasty and stenting or coronary artery bypass grafting. The long term success of both of 
these strategies is limited by the development of restenoses. In addition, many patients are 
still not suitable for conventional treatments. The only hope for those patients could be 
therapeutic arteriogenesis 3, a non-invasive treatment using growth factors, gene or cell 
therapy in order to create endogenous “bypassing” vessels.  
 
1.1. Forms of vascular growth 
 
Three different forms of vessel growth are described, of which after birth, only two 
can be observed: angiogenesis and arteriogenesis. 
Angiogenesis is the de novo formation of capillary networks by sprouting of endothelial cells 
from pre-existing postcapillary networks. 
Arteriogenesis refers to the growth of pre-existing collateral arterioles leading to the 
formation of large conductance arteries that can substitute for an occluded artery.  
In the embryo, basic blood vessel growth processes through vasculogenesis, which is the in 
situ differentiation of angioblasts into endothelial cells that form the primary vascular 
network. 
Vasculogenesis is initiated by haemangioblasts (common precursors for both 
endothelial and haematopoietic cells) in the yolk sac that create cellular aggregates, known as 
blood islands 4. Cells of the inner layer of these aggregates differentiate into haematopoietic 
precursors and cells of the outer layer give rise to precursors of endothelial cells. The earliest 
markers common to endothelial and haematopoietic precursors have been identified as CD31, 
CD34 and vascular endothelial growth factor receptor type-2 (VEGFR-2) 5. Angioblasts 
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(endothelial cell precursors) can migrate extensively until they differentiate. Some growth 
factors like vascular endothelial growth factor (VEGF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), basic fibroblast growth factor (bFGF) and insulin-like growth 
factor-1 (IGF-1) stimulate their differentiation and mobilization 6,7,8. 
In summary, vasculogenesis leads to the primary, immature vasculature. The further 
development of the embryonic vascular system is initiated by angiogenic growth processes. 
 
1.2. Mechanisms of angiogenesis 
 
The term angiogenesis was introduced in 1935 by Hertig for the description of 
placental vessel growth 9. In 1971, Folkman used this term for neovascularization 
accompanying tumor growth 10. 
Angiogenesis describes the formation of new capillary networks from pre-existing 
postcapillary microvessels. This process involves the enlargement of venules and can proceed 
via three mechanisms: by extending of sprouts from sides and ends of pre-existing vessels 
(sprouting angiogenesis), by longitudinal division of the pre-existing vessel by pillars of peri-
endothelial cells (intussusception) or by transendothelial cell bridges formation which 
separate the pre-existing vessel into capillaries 11. Newly developed capillaries reach a 
diameter of 5 to 8 µm. 
Angiogenesis is induced in response to tissue hypoxia and initiated by the activation of 
endothelial cells. Several hypoxia inducible transcription factors (HIFs), such as HIF-1β, HIF-
1α and HIF-2α, are upregulated. They bind to specific DNA sequences, hypoxia-response 
promoter elements, which regulate the transcription of several genes that are involved in the 
cellular response to hypoxia. For example, HIFs bind to the promoter of the vascular 
endothelial growth factor gene, which induces expression of VEGF, the strongest known 
angiogenic factor 12. 
The activation of endothelial cells by hypoxia is followed by a nitric oxide (NO) 
mediated vasodilation of the parent vessel. VEGF, upregulated by NO 13, is responsible for 
increased vascular permeability followed by extravasation of plasma proteins. The latter serve 
as a scaffold for migrating endothelial cells. The glycoprotein angiopoietin-1 is a natural 
inhibitor of vascular permeability and protects the vasculature against plasma leakage which 
could lead to the circulatory collaps or intracranial hypertension 14. 
1. Introduction - 3 -
Basement membrane degradation and extracellular matrix invasion are the next steps 
in angiogenesis and they are dependent on proteases and protease inhibitors. Many enzymes 
are involved in this process including matrix metalloproteases (MMPs), chymases, 
heparanases and serine proteases. The two plasminogen activators u-PA and t-PA convert the 
plasma protein plasminogen to plasmin, which subsequently activates several MMPs and 
degrades structural proteins such as laminin, fibronectin etc 15.  
After dissolving of the physical barriers, proliferating endothelial cells can migrate to 
distant sites. This migration is mediated by chemotactic factors released from various cells 
such as fibroblasts, monocytes, mast cells etc. Angiopoietin-2 is involved in endothelial cell 
migration by detaching inter-endothelial cell contacts and loosening the peri-endothelial 
matrix 16. Growth factors involved in the proliferation of endothelial cells are VEGF and its 
receptors, placental growth factor (PlGF), fibroblast growth factor (FGF) and platelet–derived 
growth factor (PDGF). There are several inhibitors of endothelial cell proliferation such as 
angiostatin, endostatin, antithrombin III and interferon β 14. NO terminates the proliferative 
actions of growth factors and promotes the formation of vascular tubes 17. 
The next step in angiogenesis is the formation of a capillary lumen. This is caused by 
thinning of endothelial cells and fusion of pre-existing vessels. Activators of this process are 
VEGF, angiotensin-1 and αvβ3 integrin. An endogenous inhibitor of lumen formation is 
thrombospondin-1 14. 
Endothelial cells of a newly formed vessel stop to migrate and their survival is controlled by 
apoptosis. Remodeling and „pruning” of capillary–like vessels results into a structured 
network of branching capillaries. 
In adult organisms, angiogenesis contributes to various physiological and pathological 
processes such as wound healing, fracture repair, reproduction, tumour growth, retinopathy 
etc. Understanding the mechanisms of angiogenesis was thought to help forming the base for 
therapeutic applications in treatment of ischemic cardiovascular diseases or cancer. However, 
some clinical trials (e.g. VIVA) did not show expected results in treatment of ischemic heart 
diseases with angiogenic growth factors (e.g. VEGF). The possible reason is that because of 
their limited ability to conduct blood, capillaries cannot substitute for an occluded artery. In 
contrast, the stimulation of arterial growth could be a promising therapeutic strategy. 
 
 
 
 
1. Introduction - 4 -
1.3. Mechanisms of arteriogenesis 
 
1.3.1. General principles of arteriogenesis 
 
After an acute occlusion or severe stenosis of a major artery, a steep pressure gradient 
between the high-pressure pre-occlusive area and the low-pressure post-occlusive region 
develops. Blood flow is now redirected along this pressure gradient, thereby recruiting the 
pre-existing collateral network. The increased blood flow velocity within the collateral 
network leads to the generation of fluid shear stress along the collateral endothelium. A 
sustained increase in fluid shear stress is the main stimulus for the activation of endothelial 
cells. The activated endothelium produces a number of cell adhesion molecules (e.g. ICAM-1) 
and cytokines (e.g. MCP-1), of which the latter attract circulating blood cells 18. It was 
suggested that the attraction of monocytes to the vascular wall is followed by their tethering, 
rolling and transmigration through the endothelium 19. The presence of monocytes and 
macrophages was proposed to be important for the development of collateral arteries, since 
they are producers of numerous cytokines (e.g. MCP-1), growth factors (e.g. TNF-α, b-FGF) 
and matrix metalloproteases (MMPs). MCP-1 acts as a chemoattractant for monocytes, TNF-
α is an inflammatory mediator, b-FGF is a mitogen for both endothelial and smooth muscle 
cells and MMPs degrade the extracellular matrix and create space for the growing artery. 
The presence of pre-existing collateral arteries was first described in 1669 by the 
English anatomist Lower, who had observed them in the heart. Later studies showed that 
collateral vessels have the ability to grow by proliferation of endothelial and smooth muscle 
cells which results in an increase of the collateral diameter up to 20 times 20. As a result of a 
twenty-fold increase in collateral diameter and increased number of collaterals, blood flow 
restoration can reach 30 to 40 percent of the origin value. Pre-existing collateral arterioles 
usually have an internal diameter between 30 and 50 µm and create an arcade-like network 
that interconnects territories of arterial subbranches 21. Pre-existing collaterals are thin-walled 
conduits composed of the endothelial layer, lamina elastica interna and one or two layers of 
smooth muscle cells. The presence and development of these interconnecting vessels varies 
among species and within individuals 22. Pre-existing collaterals have the ability to increase 
the lumen by growth and not only by vasodilation.  
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1.3.2. Biomechanical forces in arteriogenesis 
 
In 1893, the German anatomist Thoma published the so called “Law of 
Histiomechanics” which describes the relationship between the size of an artery and the 
velocity of blood flow within it 23. According to this law, large vessels with a low flow tend to 
reduce their lumen, whereas small vessels with a high flow tend to widen it (like collateral 
vessels). As mentioned before, after a relevant stenosis of a major artery occurs, blood flow is 
redistributed via interconnecting vessels that connect a high-pressure with a low-pressure 
region. The pressure gradient between two territories causes an increased fluid shear stress 
(FSS) within the interconnecting arteries. FSS is directly proportional to the blood flow 
velocity and inversely proportional to the cube of the vessel radius. It ranges from 20 to 30 
dynes/cm 24. The important role of FSS for arteriogenesis was demonstrated in an experiment 
using a rabbit ischemia hind limb model by performing an arterio-venous shunt distally to the 
femoral artery occlusion. Artificially increased FSS within collateral arteries of the shunted 
hind limb led to a 4-fold increase of collateral flow compared with the contra-lateral ligated 
but not shunted limb 25. 
 
1.3.3. Remodeling of collateral vessels 
 
Remodeling of a pre-existing arteriole into a large artery (arteriogenesis) has some 
common features with atherosclerotic remodeling which also includes monocyte invasion and 
neointima formation. However, remodeling of collateral arteries is unique in its extent. The 
remodeling process starts with the loosening of intercellular connections between smooth 
muscle cells, which results in a dilatation of the pre-existing arteriole. This is followed by an 
increase in the vascular permeability of the arteriole, mediated through VEGF, and leads to a 
plasma leakage. Extravasated plasmatic proteins are probably involved in the formation of 
new extracellular matrix. Subsequently, the arteriole is invaded by monocytes and 
lymphocytes. Endothelial proliferation is followed by a disruption of the internal elastic 
membrane and circular smooth muscle cells of the pre-existing artery undergo apoptosis 26. 
The extracellular matrix is digested by matrix metalloproteases to create space for a growing 
artery. Proliferating smooth muscle cells (SMC) are transformed from the contractile to the 
synthetic phenotype and create a new extracellular matrix and a new internal elastic 
membrane 22. Remodeled collateral arteries have similar histological characteristics like 
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normal conductive arteries except from increased collagen content between smooth muscle 
cell layers in the media and an increase in vessel length which causes a typical tortuous 
pattern.  
During later stages of arteriogenesis, the regression of smaller collaterals and the 
maturation of larger collaterals to optimized tube-like blood vessels can be observed 
simultaneously. This effect has been called pruning 24. Pruning may be based on the fact that 
due to higher resistance in small collaterals blood flow is limited which leads to lower shear 
stress within these small vessels, while larger vessels with lower resistance conduct increased 
blood flow. This in turn means higher shear stress which is the driving force for the 
maturation process.  
 
1.3.4. Time course of arteriogenesis 
 
Histological changes during arteriogenesis can be divided into four stages 18,27. 
Despite minor overlap of the phases, this scheme can be used for a description of time course 
of the collateral development.  
The initial phase starts after the vessel occlusion. Transcription factors are upregulated 
within 30 minutes and mediate expression of adhesion molecules, cytokines and growth 
factors. Endothelial cells are activated by shear stress and express both intercellular and 
vascular adhesion molecules (ICAM and VCAM). Blood monocytes are attracted to the 
endothelium by monocyte chemoattractant protein-1 (MCP-1) and bind to endothelial cells 
via their integrin receptors LFA-1 and Mac-1. The activated endothelium is characterized by 
swelling and oedema.  
The proliferation phase begins 24 hours after arterial occlusion and peaks at day three 
to seven. During this phase, an increased mitotic and proliferative activity of endothelial cells, 
smooth muscle cells and fibroblasts can be observed. Blood monocytes migrate through the 
vessel wall and accumulate in the adventitia and perivascular space of collateral arteries. 
Monocytes and macrophages secrete TNF-α and FGF-2 to induce an inflammatory 
surrounding and matrix-metalloproteases to digest the extracellular matrix. 
During the synthetic phase, endothelial and smooth muscle cells assume a synthetic 
phenotype. The lamina elastica interna is digested by elastases allowing smooth muscle cells 
to migrate. Accumulated monocytes and macrophages start to degrade and adhesion 
molecules on endothelial cells are no longer expressed.  
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The maturation phase starts about two weeks after arterial occlusion. Smooth muscle 
cells restore a contractile phenotype. Proliferation activity is decreased to a lower level of 
activity. The vessel numbers and structure are already determined. 
 
1.4. Differences between angiogenesis and arteriogenesis 
 
After the experimental occlusion of a coronary or a peripheral artery, both 
angiogenesis and arteriogenesis can in principle be observed. Both processes differ in 
induction, mechanisms, localization and involvement of growth factors and circulating cells. 
While angiogenesis is induced by hypoxia and therefore occurs in the ischemic region distant 
to the occlusion site, the stimulus for collateral growth is an increased shear stress caused by 
increased collateral blood flow. Sustained increase of shear stress activates the collateral 
vessel endothelium. In the ischemic tissue, upregulation of VEGF can be detected, whereas in 
the tissue surrounding the occlusion VEGF expression has not been found 28.  
Thin layered pre-existing collateral arteries have to undergo remodeling and growth with the 
assistance of growth factors and cytokines produced from circulating blood cells, unlike 
angiogenesis, where remodeling does not occur. Growth factors and cytokines reported to be 
involved in arteriogenesis are TGF-β, MCP-1 and GM-CSF, whereas VEGF, TGF-α and a-
FGF were shown to participate in angiogenesis 29. The accumulation of monocytes was 
proposed to be specific for arteriogenesis, but not for angiogenesis. Furthermore, only true 
collateral arteries have the ability to compensate for blood flow deficiencies after arterial 
occlusions, because as stated in Hagen Poiseuille’s law, the ability to conduct blood refers to 
the fourth potency of the vessel radius. Consequently, capillaries are not recruited to blood 
conductance over larger distances. 
 
1.5. Recruitment of peripheral blood cells 
 
After onset of ischemia, two different types of cells were previously reported to be 
recruited from the peripheral circulation: monocytes and endothelial progenitor cells 27. The 
invasion of peripheral blood cells is mediated by chemoattraction and the main role of these 
cells is to produce cytokines and growth factors and to create an inflammatory environment. 
Platelets also adhere to the collateral endothelium and produce interleukin-4, which increases 
the expression of adhesion molecules 22. Basophils, which transform into mast cells after their 
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migration into a tissue from blood circulation, produce heparin and other substances which 
are probably involved in collateral artery growth. T-cells have been also observed to be 
accumulated in the adventitia of a growing artery and they participate in destroying of 
neighboring cells to create space for a growing artery 24.  
 
1.5.1. Monocytes and macrophages 
 
1.5.1.1. Physiological functions 
 
Monocytes and macrophages were classified by Aschoff as cells of the reticulo-
endothelial system. In 1972, Van Furth proposed the mononuclear-phagocyte system 
classification.  
Monocytes are generated in the bone marrow and pass through several developmental 
stages: stem cells, committed stem cells, monoblasts, promonocytes, monocytes in bone 
marrow, monocytes in peripheral blood and macrophages in tissue. The process of 
haematopoiesis is controlled by growth factors. Differentiation from pluripotential stem cells 
to myeloid progenitor cells is mediated by IL-3. Further differentiation to 
monocyte/macrophage lineage is mediated by M-CSF and GM-CSF. Moreover, TNF-α has 
also been implicated in growth regulation of macrophage precursors. 
Blood monocytes represent 4-8 % of all blood leukocytes. Circulating monocytes 
possess migratory, chemotactic, pinocytic and phagocytic activities. After 2 or 3 days in the 
blood circulation, monocytes migrate through the vessel wall (diapedesis) and commit 
differentiation to become tissue macrophages 30. In response to invasive stimuli and 
inflammation, monocyte numbers increase dramatically.  
Macrophages can be divided into resident and inflammatory cells. Resident tissue 
macrophages are present in large numbers in tunica submucosa, pulmonary alveoli, 
juxtaglomerular spaces in kidneys, liver, spleen, lymph nodes, bone marrow, serous fluids 
(pleural and peritoneal), skin etc. but are very rare in skeletal muscles and around blood 
vessels (own unpublished observations). Resident tissue macrophages are relatively quiescent 
cells with low oxygen consumption and little or no cytokine production. Their main function 
is phagocytosis and chemotaxis. The population is maintained by local proliferation of 
progenitor cells and not via monocyte influx, and the life span of resident macrophages is 
between 6 and 16 days. Macrophages isolated from different anatomical sites possess diverse 
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phenotypes and capabilities. Inflammatory macrophages are present in exsudates. They can be 
characterized by specific markers like peroxidase activity and since they are derived 
exclusively from monocytes, they share similar properties.  
Macrophages in their activated state can secrete a large number of substances (shown 
in table 1) and their biologic activity range from induction of cell growth to cell death. They 
can be primed for activation by IFN-γ, M-CSF, GM-CSF, TNF-α etc. In the activated state, 
they exhibit enhanced MHC class II expression, antigen presentation, oxygen consumption 
and reduce their proliferative capacity. Macrophages can be deactivated by prostaglandin E2 
(PGE2) and the so called macrophage deactivating factor (MDF) which was isolated from a 
tumor cell supernatant 31. 
 
Polypeptide hormones IL-1, IL-6, IL-8, TNF-α, IFN-α, IFN-γ, 
PDGF, FGF, TGF-β, GM-CSF, G-CSF, 
erythropoietin 
Complement components C1, C2, C3, C4, C5, factors B, D, P 
Coagulation factors V, VII, IX, X, plasminogen activator 
prothrombin, plasmin inhibitors 
Bioactive lipids PGE2, PGF2, PGI2, tromboxans 
LTB4, LTC4, LTD4, LTE4 
Enzymes elastase, collagenase, hyaluronidase, arginase 
acid proteases, peptidases, lysozyme,  
lipases, ribonucleases, phosphatases   
Protease inhibitors α2-macroglobulin, plasminogen activator 
inhibitors, collagenase inhibitor    
Proteins of extracellular matrix fibronectin, thrombospondin, 
chondroitin sulfate proteoglycans 
Reactive oxygen intermediates superoxide, hydrogen peroxide, hydoxyl 
radical, hypothalite 
Reactive nitrogen intermediates nitric oxide, nitrites, nitrates  
Others thymidine, uracil, uric acid, neopterin 
 
Table 1.  Secretory products of macrophages. Modified from Nathan et al. 1987.  
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Macrophages are involved in immune, homeostatic and inflammatory responses. They 
provide an immediate defense against foreign elements prior to leukocyte immigration. 
Macrophages participate in both specific immunity via antigen presentation and IL-1 
production and unspecific immunity by phagocytosis of bacterial, viral, fungal and neoplastic 
pathogens. 
 
1.5.1.2. Monocytes and arteriogenesis 
 
The attachment of monocytes to the collateral endothelium (Fig. 1) was observed for 
the first time in canine heart 32.  
 
 
Fig. 1.  Monocytes adhere to the endothelium of the growing collateral artery. (Schaper et al. 
1976) 
 
Later studies revealed that monocytes which accumulate in the perivascular space of 
growing collateral arteries 18 produce growth factors and cytokines like bFGF, TNF-α 33 and 
VEGF 34. Conversion of monocytes into an active state occurs by binding of stimulatory 
factors such as cytokines and other cell-derived molecules. Monocytes are attracted to the 
collateral endothelium by cytokines like PlGF or MCP-1. The latter is expressed by shear 
stress-activated endothelial cells 35. The expression of MCP-1 is regulated by growth factors 
(e.g. VEGF and FGF-2). In the rabbit ischemia hind limb model, a local administration of 
MCP-1 into the proximal stump of the occluded artery via an osmotic minipump resulted in 
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an increased density of collateral arteries in the thigh area and increased collateral 
conductance 35. Our study showed that targeted disruption of the MCP-1 receptor, CCR-2, in 
mice almost abolished collateral artery growth 36 due to the impaired monocyte recruitment. 
Monocyte adhesion to the endothelium is mediated by specific adhesion molecules on 
monocytes termed integrins and by both intercellular and vascular cell adhesion molecules 
(ICAM and VCAM) on endothelial cells. Integrins are heterodimeric cell surface receptors 
composed of two trans-membrane glycoproteins: a variable α-chain and a non-variable β-
chain. The β2-subfamily represents leukocyte-specific integrins such as LFA-1 (leukocyte 
function associated antigen-1) and Mac-1. Integrins mediate attachment of cells to the matrix, 
cell-to-cell connections, and regulate intracellular signal transduction 37. Monocytes bind to 
the ICAM-1 molecules on endothelial cells by their Mac-1 receptor, invade the vascular wall 
and accumulate in clusters in the adventitia and the perivascular space of the growing artery. 
It was shown that an intravenous infusion of anti-ICAM-1 antibodies diminished monocyte 
attachment and arteriogenesis 38. Monocytes also express VEGF receptor 1 (also known as 
Flt-1), which binds to VEGF A 39. Incubation of monocytes with VEGF enhances surface 
expression of LFA-1 and Mac-1 40 , thus enhances monocyte migration through the vessel 
wall.  
 
1.5.2. Endothelial progenitor cells 
 
Endothelial progenitor cells (EPC) were identified in the blood as a circulating cell 
population 41 which co-expresses both endothelial cell markers (VE-Cadherin, VEGFR-2) and 
hematopoietic stem cell markers (CD34, CD133). EPC are very rare in the blood but can be 
mobilized from the bone marrow into the circulation by vascular trauma, ischemia and 
administration of cytokines like G-CSF and GM-CSF. After mobilization with G-CSF, only 2 
% of all CD34 positive cells also express CD133 and VEGFR-2 6. EPC have been shown to 
migrate to the place of physiological or pathological angiogenesis 42. Their potential and 
mechanisms are controversially discussed. 
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1.5.3. Other cells involved in arteriogenesis 
 
Mast cells were found in aggregates in the adventitia of growing collateral arteries. It 
has been shown that they produce growth factors like b-FGF, VEGF, platelet activating factor 
and cytokines 43. Their role in arteriogenesis has yet not been completely elucidated. 
Bone marrow-derived stem cells have been proposed to circulate in adult organisms 
and to be recruited to sites of pathological and physiological neovascularisation 41,44. Further 
promising studies revealed that transplantation of these cells could augment perfusion of an 
ischemic tissue 45,46. The suggested mechanism of perfusion improvement was due to the 
incorporation of bone marrow-derived cells into the adult vasculature. In contradiction, recent 
studies showed that these cells did not act by trans-differentiation into the organ-specific cells, 
but they produced angiogenic growth factors and cytokines, therefore described as “cytokine 
factories”, necessary for the collateral artery growth 47,48.  
 
1.6. Vascular growth factors and chemokines 
 
1.6.1. Growth factors 
 
More than three decades ago, a tumor growth factor was discovered which was found 
to be mitogenic for endothelial cells 10. This factor was later identified as a member of the 
fibroblast growth factor family. Since that time, many angiogenic proteins have been 
discovered. Later studies on growth factors have shown that collaterals can develop only in 
the presence of growth- or angiogenic factors and when their receptors are expressed. Infusion 
of growth factors into healthy hearts did not induce angiogenesis probably because of the 
absence of their receptors in normal tissue 26. Hence, the regulatory mechanism of vascular 
cell division is the availability of growth factor receptors and not the presence of a ligand. A 
list of the most important angiogenic proteins is in table 2.  
On the one hand, growth factors are involved in the stimulation of functional repair 
processes, including collateral vessel formation. On the other hand, the role of growth factors 
in tumorgenesis and cardiovascular disorders, in particular atherogenesis and restenosis, have 
been recognized 49. The modulation of growth factors-related signals was suggested to be 
used for the treatment of cardiovascular diseases.  
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Acidic fibroblast growth factor (aFGF) Granulocyte colony-stimulating factor (G-CSF) 
Angiogenin 1 Placental growth factor 
Angiogenin 2 Platelet-derived growth factor (PDGF) 
Angiopoietin-1 Proliferin  
Angiopoietin-2 Thrombospondin (TSP) 
Basic fibroblast growth factor (bFGF) Transforming growth factor-α(TGF-α)   
Fibroblast growth factor 3 (FGF-3) Transforming growth factor-β (TGF-β) 
Fibroblast growth factor 4 (FGF-4) Tumor necrosis factor-α (TNF-α) 
Fibroblast growth factor 5 (FGF-5) Vascular endothelial growth factor 121 (VEGF-121) 
Fibroblast growth factor 6 (FGF-6) Vascular endothelial growth factor 145 (VEGF-145) 
Fibroblast growth factor 7 (FGF-7) Vascular endothelial growth factor 165 (VEGF-165) 
Fibroblast growth factor 8 (FGF-8) Vascular endothelial growth factor 189 (VEGF-189) 
Fibroblast growth factor 9 (FGF-9) Vascular endothelial growth factor 206 (VEGF-206) 
Heparin Vascular endothelial growth factor B (VEGF-B) 
Heparin affinity regulatory peptide Vascular endothelial growth factor C (VEGF-C) 
Hepatocyte growth factor (HGF) Vascular endothelial growth factor D (VEGF-D) 
Insulin-like growth factor Vascular endothelial growth factor E (VEGF-E) 
Interleukin 8 Vascular endothelial growth factor F (VEGF-F) 
 
Table 2.  List of angiogenic proteins. Modified from Kutryk et al. 2003. 
 
Growth factors regulate various cellular functions including proliferation, migration, 
differentiation and survival. They act through binding to their specific, membrane-bound cell 
surface receptors (e.g. tyrosine kinase type receptors). This activates a specific signal 
transduction cascade which can reach the nucleus and modulate proliferation and 
differentiation or it can directly modulate the function of cellular proteins. The majority of 
growth factors (e.g. PDGF, bFGF and VEGF) are positive regulators of the cell cycle and they 
stimulate cell proliferation and migration. A negative regulation of the cell cycle (e.g. by 
TGF-β) leads to a growth arrest. The interaction between growth factors and their receptors is 
increasingly complicated by the fact that different isoforms of a growth factor can bind to the 
same or different receptors. This has to be considered when a therapeutic strategy is aimed to 
block the interaction between a specific growth factor and its receptor. 
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Growth factors involved in collateral artery growth are fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF) and potentially also granulocyte-macrophage colony-
stimulating factor (GM-CSF). FGF is involved in extracellular matrix modulation, cell 
replication and interactions related to capillary tubule formation. Transgenic overexpression 
of FGF-1 in the heart leads to increased arteriolar density and branching 50. PDGF is a strong 
mitogen for mesenchymal cells such as vascular smooth muscle cells (VSMC) and fibroblasts. 
The PDGF-BB isoform is the most potent chemotactic agent for VSMC 51. 
 
1.6.1.1. Granulocyte-macrophage colony-stimulating factor 
 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was the first colony-
stimulating factor being responsible for the mobilization of myeloid progenitor cells from the 
bone marrow. It belongs to the family of glycoprotein cytokines that act by stimulating 
proliferation, maturation and function of haematopoietic cells 52. 
The human GM-CSF gene has been mapped to the long arm of chromosome 5, together with 
M-CSF, IL3, IL4 and IL5. GM-CSF can be synthesized by macrophages, T and B 
lymphocytes, fibroblasts, endothelial cells and mast cells in response to specific activating 
signals. T lymphocytes and macrophages are activated by immune or inflammatory stimuli. 
Fibroblasts and endothelial cells are activated by monokines such as IL-1 and TNF. 
Human GM-CSF was identified in 1984. It is a glycoprotein with molecular weight of 22 kD. 
Human and murine GM-CSF cDNAs encode polypeptides of 144 and 141 amino acids, 
respectively. Two intra-chain disulfide chains are important for its biologic activity. Despite a 
54 % identity at the amino acid level between murine and human GM-CSF, no cross-species 
reactivity was observed 52. 
GM-CSF acts as a growth factor both in vitro and in vivo, stimulating proliferation 
and maturation of myeloid progenitor cells, eosinophils, neutrophils and monocytes. 
Furthermore, GM-CSF enhances the phagocytic activity of neutrophils, eosinophils and 
macrophages and increases antibody-dependent cell-mediated cytotoxicity towards tumor 
cells. The most important clinical application of GM-CSF is to counter the myelosuppressive 
side effects of chemotherapy and radiation therapy, to enhance host defense in 
immunocompromised states and to accelerate recovery after bone marrow transplantation. 
Moreover, a potential antineoplastic activity has been reported 53. Proposed mechanisms 
include secretion of molecules that are cytotoxic to tumor cells. Recently, an anti-atherogenic 
effect of GM-CSF treatment was observed in a study performed on hyperlipidemic rabbits 54. 
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Histological studies showed reduced intimal thickening and areas of atherosclerotic lesions in 
the aortic arch of rabbits treated with GM-CSF compared to controls. Moreover, GM-CSF 
reduces both total and HDL cholesterol levels in patients 55. 
Potential arteriogenic effects of GM-CSF could be associated with monocytes/macrophages. 
The suggested mechanisms of action of GM-CSF are by releasing immature monocytes from 
the bone marrow and by increasing life span of monocytes/macrophages 56. 
 
1.6.2. Chemokines 
 
Chemokines are a group of chemotactic cytokines responsible for attraction, migration 
and activation of leukocytes. Chemokines act locally in a paracrine and autocrine way via 
binding to specific cell surface receptors. There are about 50 human chemokines that are 
divided into the four major families according to their structure and functions. “CC-
chemokines”, which contain two cysteine residues adjacent to each other, attract mononuclear 
cells to sites of inflammation. The best studied chemokines of this group are the monocyte 
chemoattractant proteins (MCPs) 1-5. MCP-1, also known as CCL2 57, is a potent 
chemoattractant for monocytes, T lymphocytes and basophils 58. MCP-1 mediates monocyte 
migration during collateral vessel growth 35. Other members of the CC-chemokine family are 
macrophage inflammatory proteins (MIPs) α, β, γ and RANTES. Members of “CXC-
chemokines”, e.g. interleukin-8, attract polymorphonuclear leukocytes. The third family, 
“CX3C-chemokines”, is represented by fractalkine which is a chemoattractant for monocytes, 
T lymphocytes and natural killer cells. 
 
1.7. Prostacyclins 
 
Prostacyclin (PGI2) is the most abundant product of arachidonic acid in vascular 
tissues. Arachidonic acid is released from phospholipid pools by phospholipase A2 and 
converted to prostaglandin H2 (PGH2) by the cyclooxygenase system (COX). PGH2 is 
subsequently converted to PGI2 by PGI2 synthase. PGI2 is labile and undergoes spontaneous 
inactivation within minutes in vivo. For clinical application, several stable synthetic analogues 
have been developed and are commercially available like Iloprost, Cicaprost and 
Carbaprostacyclin.  
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Prostacyclins exhibit vasoactive, mitogenic and differentiating properties. The 
important role in vascular physiology is based on their anticoagulatory and vasodilative 
activities. PGI2 signaling pathway occurs through cell surface receptors (IPs) with a 
consequent increase of intracellular cAMP, and through peroxisome proliferator-activated 
receptors (PPARs), located in the nucleus 59. The PGI2 analogue Cicaprost acts only on IP 
receptors. Human monocytes express high levels of IP receptor mRNA. It has been proposed, 
that PGI2 may induce VEGF production in human monocytic cell line via interaction with IP 
receptors on the cell membrane and thus may have a potential angiogenic effect 60. Moreover, 
stimulation of monocytes with Cicaprost increases production of inducible NO synthase in 
coculture with lipopolysaccharide and may contribute to the increased NO production during 
inflammation 61. In addition, PGI2 was reported to modulate cell fate through PPARs by 
induction or suppression of apoptosis62. Whereas intracellular prostacyclin formed by 
prostacyclin synthase in human embryonic kidney cells promotes apoptosis, treatment of cells 
with extracellular prostacyclin reduces apoptosis.  
Based on the fact that prostacyclins may delay the differentiation of monocytes into 
macrophages, we investigated the effect of monocyte priming with PGI2 on their arteriogenic 
properties. 
 
1.8. Study objectives 
 
The objective of the present study was to investigate the role of monocytes for 
arteriogenesis. In our experimental settings, injections of monocytes were used to investigate 
the blood flow recovery after the experimental femoral artery occlusion in mice. An important 
focus was set on the concentration of blood monocytes. Furthermore, the influence of a 
systemic treatment with GM-CSF in a mouse ischemic hind limb model was tested. The 
present study was designed according to the several queries: 
1. Is there a correlation between the concentration of circulating monocytes and the 
extent of arteriogenesis? 
2. What is the origin of monocytes/macrophages which can be found around growing 
collateral vessels? 
3. Can arteriogenesis be enhanced by manipulating with the differentiation process of 
monocytes? 
4. Does GM-CSF play a role in arteriogenesis? 
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5. Does a synergistic effect arise from a combination of GM-CSF treatment and 
monocyte injections? 
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2. Material and methods 
 
2.1. Overview 
 
Murine monocytes were isolated from peripheral blood and after pre-treatment 
injected into mice with acute experimental femoral artery occlusion. Within the observation 
period of three weeks, blood flow recovery to the ischemic hind limb was monitored using 
laser Doppler Imaging (LDI) at certain time points. Three weeks after operation, animals were 
sacrificed, hind limb vessels were visualized using angiography and adductor muscles were 
sampled for histological analysis. 
 
density gradient cenrifugation
eye punction
injection
identification
isolation incubation
 
Fig.2.  Scheme of the methods used for monocyte isolation and injection. 
 
All animal experiments were performed with the approval of the bioethic committee of 
the Regierungspräsidium Darmstadt and according to Section 8 of the German Law for the 
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Protection of Animals, which conforms to the US National Institutes of Health (NIH) 
guidelines. 
 
2.2. Animals 
 
For all experiments, male BALB/cAnNCr1 mice were used which had been purchased 
from Charles River Laboratories, Germany. The animals were 9 to 14 weeks old, weighted 
between 20 and 25 grams and were free of pathogens. The mice had free access to water and 
chow. Housing and handling of animals was in accordance with the German Law for the 
protection of animals.  
 
2.3. Isolation of murine blood monocytes 
 
BALB/cAnNCr1 mice were used as blood donors. Mice were anaesthetized with an 
intraperitoneal injection of 10 % Ketamin (Medistar) and 2 % Xylazin (Medistar) in 0.9 % 
NaCl solution and heparinized with 0.1 ml of Heparin (500 IU; Roche). After 5 minutes, 
blood was obtained from orbital vessels by penetration with heparinized capillaries. These 
capillaries were slightly turned against the orbital bone. After collecting approximately 800 µl 
blood which was sampled in EDTA-coated tubes, mice were immediately sacrificed. 
 
Narcosis : 1 ml Ketamin (10 % ) 
                 1 ml Xylazin ( 2 % ) 
                 2 ml NaCl ( 0.9 % )  
0.08 ml of narcosis was used per mouse. If required, 0.02 ml of the same solution were 
injected at a later time point. 
 
2.3.1. Density gradient centrifugation 
 
The collected blood was diluted in an equal volume of 0.9 % NaCl. 10 ml of the 
diluted blood was layered over 3 ml Ficoll-Hypaque solution (Amersham Biosciences) in 15 
ml centrifugation tubes. The density gradient centrifugation was performed for 20 min at 20 
°C and 2300 rpm (1200 x g). After centrifugation, mononuclear cells which had accumulated 
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in a band above the gradient solution were removed using a pipette. Harvested mononuclear 
cells were diluted 1 : 2 with 0.9 % NaCl and centrifuged for 10 min at 4 °C and 1800 rpm 
(600 x g). The supernatant was removed and the pellet was resuspended in 0.9 % NaCl. 
Afterwards, the centrifugation was repeated as before.  
 
2.3.2. Staining of monocytes using fluorochrome-conjugated monoclonal antibodies 
 
To specifically identify the monocytes, mononuclear cells were incubated with 10 µl 
of a phycoerithrin (PE)-conjugated murine monoclonal antibody against CD 11b (Beckman-
Coulter) for 30 min at 4 °C. Before sorting, remaining erythrocytes were lysed with 1 ml of 
Lysis-buffer for 1-5 min and washed with 0.9 % NaCl.  
 
Lysis-buffer: 
Ammoniumchloride        1.605   g 
Potassiumhydrogencarbonate 500.6    mg 
EDTA 20.2   mg 
Distilled water  500       ml 
pH was adjusted to 7.4 
 
2.3.3. Flow cytometry-based monocyte sorting 
 
Flow cytometry is used to analyse the distribution of the cells or cell surface molecules 
on the cells in a suspension. It serves, for example, for characterization of leukocytes or for 
identifying progenitor cells from the peripheral blood.  
Cells of interest can be labeled with a monoclonal antibody specific to a cell antigen. The 
antibody is conjugated with a fluorochrome. Labeled cells can be further analyzed according 
to their forward and side scatter characteristics and – in case of monocytes - their CD 11b 
expression. Statistical analysis and counting of the labeled cells is performed by software. In 
order to isolate the cells of interest, flow cytometry-based sorting of suspension cells can be 
performed achieving high purity and yield of isolated cells. 
In our experiments, a high speed cell sorter (EPICS Altra, Beckman-Coulter, USA) was used 
for isolation of monocytes from the mononuclear cell fraction. Prior to isolation, the sorter 
was set up and sheath fluid was equilibrated to a constant temperature of 8-10 °C using an 
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external cooling water bath. Sort settings were established as shown in table 3. To maximize 
cell viability, the system was run at a pressure of 12 psi using collection tubes coated with 
bovine serum albumin.  
 
Sheath fluid : 0.9 % NaCl 
Frequency : 28.9 kHz 
Drive : 20-30 % 
Delay : 33 
 
Tab. 3.  Sort settings used to isolate mouse monocytes using the EPICS Altra cell sorter.  
 
 
Fig. 3.  Principle of flow cytometry and sorting. 
 
As shown in figure 3, the cell suspension was directed into a sheath stream. The 
sample stream was disrupted into drops by a piezoelectric crystal at a frequency of 28.9 kHz. 
A laser beam was directed to the stream before it was disrupted into the drops. Emitted light 
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was recognized by electronic detectors. Drops which contained identified cells were deflected 
from the sample stream and collected in centrifuge tubes.  
 
2.3.4. Incubation of monocytes 
 
Isolated monocytes were centrifugated by 1800 rpm (600 x g) at 4 °C for 10 min and 
resuspended in 1 ml RPMI 1640 medium. After that, monocytes were incubated for 3 hours 
with 200 ng of rmGM-CSF (Schering) at 37 °C and 5 % CO2.  
After the incubation, monocytes were centrifuged at 1000 rpm (200 x g) for 8 min. Cells were 
resuspended in isotonic NaCl to a maximal volume of 150 µl for i.v. injection. 
 
For the next experimental group, isolated monocytes were centrifuged as described 
above, resuspended in 1 ml RPMI 1640 and subsequently incubated with 100 ng of Cicaprost 
(Schering) for 2 hours at 37 °C and 5 % CO2.    
 
The following table provides an overview on the different groups included in the study.  
 
Group Treatment Dosis N 
1 0.9 % NaCl (control)  150 µl; i.v. 24 
2 Monocytes 2 x 105 cells/mouse; i.v. 11 
3 Monocytes 3 x 105 cells/mouse; i.v.  9 
4 rm GM-CSF 500 ng; i.p. 11 
5 Monocytes and rm GM-CSF 2 x 105 cells/mouse i.v. + 1µg  
rm GM-CSF i.p. for 5 days 
10 
6 Monocytes and rm GM-CSF 3 x 105 cells/mouse i.v. + 1 µg  
rm GM-CSF i.p. for 5 days  
7 
7 Monocytes incubated with Cicaprost 2 x 105 cells/mouse + 100 ng 
Cicaprost; 2 h incubation; i.v.  
11 
8 Monocytes incubated with rm GM-CSF 2 x 105 cells/mouse + 200 ng  
rm GM-CSF; 3 h incubation; i.v. 
9 
 
Tab. 4.  Overview on different groups included in the study. 
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2.4. Animal model 
 
The study was conducted using a model of regional hind limb ischemia in mice. Mice 
were anaesthetized and pre-operative laser Doppler Imaging was carried out. The femoral 
artery was occluded and post-operative laser Doppler Imaging followed. Afterwards, isolated 
monocytes were injected into a tail vein as shown in figure 4. 
anaesthesia
LDI (pre)
operation
LDI (post)
cell injection
Fig.4.  Schematic overview on the treatment included in the animal model. 
 
2.4.1. Operation 
 
Mice were anaesthetized with 0.08 ml of a solution containing 10 % Ketamin (2 
mg/kg body weight) and 2 % Xylazin (13 mg/kg body weight) in 0.9 % NaCl solution. To 
protect the cornea against inflammation, eyes were covered with a panthenol containing 
cream. During operation mice were placed on a heated pad (37 °C) and limbs were fixed to it 
to ensure the immobilization and a good surgical access.  
The skin was cut with one incision above the ligamentum inguinale. The A. femoralis was 
separated from the V. femoralis and the N. femoralis by a blunt preparation. The femoral 
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artery was ligated distally to the A. profunda femoris (as shown in figure 5) and proximally to 
the A. genus descendens by a surgical double knot using 6-0 metric non absorbable silk 
suture. The operation area was rinsed with 0.9 % NaCl to protect the tissue from drying. 
Finally, the skin was closed with the same 6-0 metric silk suture.     
 
 
right leg                                                            left leg 
Fig. 5.  Vessels of the thigh filled with the contrast agent. Development of 4 corkscrew 
collateral arteries is visible in the occluded right leg. Arrowhead points at the ligature. Pre-
existing collaterals are visible in the left leg. Modified from Ziegelhoeffer et al. 2003. 
 
2.4.2. Injection of monocytes 
 
Isolated monocytes were resuspended in 0.9 % NaCl to a concentration of 106 
cells/ml. Mice were exposed to infrared light for 2 minutes to increase visibility of the tail 
veins due to vasodilation. After desinfection of the tail using alcoholic skin desinfection 
agent, monocytes (in 150 µl of saline solution) were injected into a tail vein. The injection 
was performed within 30 minutes after ligature of the femoral artery. 
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2.5. Laser Doppler Imaging 
 
2.5.1. Principle of laser Doppler Imaging 
 
The laser Doppler Imaging technique was developed to measure blood flow in the 
microcirculation. Since the laser penetration depth of the tissue is 1-2 mm, the method can be 
used for measurements of “fluxes” in capillaries close to the skin surface, in the underlying 
arterioles and venules and is also suitable for quantification of blood flow in mice feet.  
According to the Doppler principle, the low power light from a monochromatic laser directed 
at a tissue is scattered by moving red blood cells. In consequence, the frequency of the 
reflected light correlates with the blood, motion which is used to quantify blood flow. 
 
 
 
Fig. 6.  Scheme of a Laser Doppler Imager. 
 
The frequency range is typically 20 Hz to 20 kHz. Laser light can be directed to the tissue 
surface either via an optic fibre or as a light beam. In our laser Doppler blood flow Imager 
(LDI) the low intensity laser beam is used to scan across the tissue surface using a moving 
mirror (Fig. 6). There is no direct contact with the measured tissue. The scanned area can be 
defined and acquired data recorded and calculated. The laser Doppler Imager provides spatial 
information and has the ability to average blood flow measurements over large areas. 
The term used to describe blood flow measured by the laser Doppler technique is “flux”. It is 
the quantity proportional to the product of the average speed of the blood cells and their 
number concentration. This is expressed in arbitrary “perfusion units” and is calculated using 
the first moment of the power spectral density.  
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2.5.2. Quantification of foot blood flow in the mouse model using LDI 
 
Relative blood flow was measured in the feet of mice using a laser Doppler perfusion 
Imager (MLDI 5063; Moor Instruments, UK). Measurements were performed before 
operation, immediately after and on postoperative days 3, 7, 14 and 21.  
To achieve standardized conditions, mice were anaesthetized and maintained in a climatized 
chamber at 37 °C for five minutes before every measurement. Mice were placed on the back 
and feet were taped in parallel to each other with the plantar side down on a pad so that the 
back of the foot was exposed to the laser beam. Afterwards, a scanning region was defined. 
The pixel resolution was set at 256 x 256 and the scan rate was 4 ms/pixel for 1.7 x 3 cm area. 
The background value was determined by performing post mortem measurements and was 
subtracted from every measured value. The right-to-left ratio (occluded-to-non-occluded leg) 
was quantified for each mouse. Results are expressed as mean ± SEM. 
 
2.6. Hemoglobin oxygen saturation 
 
2.6.1. General principle of spectrophotometry 
 
Measurement of light absorption of substances for analyzing their optical properties 
and concentration can be performed using a spectrophotometer. The excitation light is 
focused by lenses and passes through a monochromator which separates it into a single-
wavelength light. One particular wavelength is selected to pass into the sample. The light 
transmitted through the sample is detected by a photodetector and converted into the electric 
current measured by galvanometer. The electric current is translated into a readable signal on 
the digital display. The measurement is based on different intensities of the excited and 
transmitted light. 
 
2.6.2. Assessment of hemoglobin oxygen saturation using spectrophotometry 
 
Oxygen saturation of hemoglobin in the mice feet was determined using a tissue 
spectrophotometer AbTisSpec (LEA Medizintechnik, Germany) measuring the absorption 
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spectrum in a wavelength range of 500 to 620 nm. The optical sensor detected local values of 
both, the saturation and hemoglobin concentration.  
Mice were placed for five minutes in a climatized chamber with a constant temperature of 37 
°C to keep standardized conditions. The optical sensor was positioned above the mouse foot. 
Measurements were performed before the operation, immediately after and on postoperative 
days 3, 7, 14 and 21. The right-to-left ratio was calculated from each measurement. Results 
were expressed as mean ± SEM.  
 
 
Fig. 7.  Oxygen saturation of hemoglobin (0-100 %). Modified from www.cephalon.dk 
 
2.7. Active foot movement 
 
After ligature of the femoral artery, due to reduced pedal blood flow circulation, mice 
typically showed an impaired active foot movement. To assess the active foot movement as a 
functional parameter, a score system was developed to describe the functional recovery of the 
occluded hind limb (Tab.5).  
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0 No use of the foot, necrosis of the foot or toes 
1 Passive movement, foot is dragged  
2 Active movement without spreading the toes 
3 Spreading of the toes is restricted, claudication 
4 Unrestricted movement 
 
Table 5.  Active movement score. 
 
Mice were placed into an empty cage and stimulated to move. The score zero was given to 
mice which did not use the foot at all. These mice often exhibited necrosis. Mice with a 
progressive necrosis were sacrificed. Mice with a passive foot movement received score one. 
The leg was not involved in movement and it was only pulled. Active movement was scored 
with two in the case, when mice could not spread toes but were already able to step with the 
occluded leg. Score three was given to mice which could spread the toes but only restricted. 
There was still an apparent claudication in the movement. Complete recovery of the foot 
movement was scored with four. In this case, no difference between occluded and non-
occluded leg was visible.  
The measurements were performed on postoperative days 3, 7, 14 and 21. Results are 
expressed as mean ± SEM. 
 
2.8. Tissue perfusion and fixation 
 
For tissue sampling which was performed three weeks after ligature of the femoral 
artery, all mice were heparinized with 0.1 ml of Heparin by an intraperitoneal injection and 
anaesthetized by injecting an overdose of Ketamin and Xylazin (10 % Ketamin, 2 % Xylazin) 
intraperitoneally. Mice were placed in a plastic dish laying on the back and limbs were spread 
and fixed. The chest and abdominal cavities were opened and the proximal part of the 
abdominal aorta was exposed, separated from the fat tissue and the vessel was cannulated. 
Subsequently, the inferior vena cava was cut. Catheters were made from a winged infusion set 
cutting off the tip of the needle and blunting the end of the needle. Hind limb vessels were 
perfused with dilatation buffer containing 0.1 % adenosine (Sigma) and 0.5 % bovine serum 
albumin (BSA; Sigma) in phosphate-buffered saline (PBS) with pH 7.4 for 4 minutes under 
the pressure of 100 cm H2O. After reaching the maximal vasodilation, the perfusion was 
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switched to 3 % paraformaldehyde (pFA; Sigma) in PBS (pH 7.4) for 10 minutes. Afterwards, 
the vessels were again perfused with PBS for 3 minutes to remove pFA which reacts with the 
gelatine. Subsequently, the bismuth-based contrast agent was infused for 2 minutes under the 
constant pressure of 200 mm Hg for 2 minutes. During perfusion with the contrast agent, mice 
were immersed in 40 °C warm water. Finally, mice were covered with ice to enhance 
gelatination of the contrast agent. 
 
Used solutions: 
PBS (phosphate-buffered saline):  
NaCl 7.948   g 
KCl 0.2       g 
KH2PO4 0.2       g 
NaHPO4 * H2O 1.775   g 
Distilled water 1          L 
pH was adjusted with HCl or NaOH to 7.4   
 
3 % pFA (paraformaldehyde): 
30 g pFA powder were added to 1000 ml PBS. While stirring, pH was slightly increased by 
adding 2 or 3 NaOH crystals to the solution. After a complete dissolving of pFA, pH was 
adjusted to 7.4 and solution was stored at –20 °C until use. 
 
Dilatation buffer: 
Adenosin 1 g 
Bovine serum albumin 5 g 
Phosphate-buffered saline 1 L 
pH was adjusted to 7.4 
 
2.9. Angiograms 
 
After one hour, mice were removed from the ice bath. Muscles of the lower limbs 
were exposed from the skin. The abdominal cavity organs were removed and the upper part of 
the body was cut off. Angiograms were taken using a Balteau radiography apparatus. For this, 
mice were placed at the bottom of a plexiglass box filled with cold water and fixed on the 
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bottom of it. A Roentgen film was placed underneath the box and was exposed for 2.5 
minutes at 20 kV and 8 mA. 
 
2.9.1. Preparation of contrast agent 
 
100 g Bismuth chloride (Merck) was added to 800 ml 18 % NaCl solution. 
Afterwards, the solution was placed on a stirrer and 32 % HCl was added dropwise while 
stirring, until bismuth chloride was completely dissolved. Then, the solution was filtrated 
through a gaze. 5 L beakers were filled with cold water. Subsequently, 250 ml of the solution 
was added dropwise into the beaker while stirring. Bismuth was let to sediment for 40 
minutes. After this, the supernatant was removed and the sediment was collected in an 
Erlenmeyer flask to finalize sedimentation. After this, the supernatant was removed and the 
bismuth was stored at –20 °C. Before using of the contrast agent, a 10 % gelatin solution in 
distilled water containing 0.01 % Sodiumazid was prepared. The bismuth solution was mixed 
with an equal amount of gelatin and incubated at 37 °C until the instillation.   
 
Used solutions: 
 
18 % NaCl: 180 g NaCl 
                    1000 ml distilled water 
10 % gelatin: 5 g gelatin  
                      50 ml distilled water  
 
2.9.2. Development of angiograms 
 
Exposed Roentgen films were developed for four minutes in the darkroom by 
immersion in Kodak LX 24 developer and after washing the films were fixed for five minutes 
in AGE fixer. After 15 minutes of water bath, the films were immersed in the distilled water 
and finally dried for 30 minutes. 
For analysis, films were scanned (Duoscan T1200, Agfa) and digitalized. 
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2.10. Tissue sampling and histology 
 
2.10.1. Sample preparation 
 
Adductor muscles of both hind limbs (ligated and non-ligated) were removed. The 
muscles were cut in triangle-like shape comprising the collateral vessel containing area. The 
basis of the triangle was cut proximally to the A. profunda femoris. The other side was cut 
laterally from the A. femoralis towards the knee and the third side connected knee with the 
medial side of the A. profunda femoris. Muscles were placed into a centrifuge tube filled with 
PBS. After 20 minutes, PBS was exchanged to 10 % sucrose in PBS and stored at 4 °C for 30 
minutes. The muscles were dehydrated in this hyperosmotic solution and dropped down to the 
bottom of the tube. Then, the solution was replaced by 25 % sucrose in PBS and stored for 
five hours at 4 °C. Subsequently, samples were removed from the sucrose and placed upright 
positioned on cork squares. Whole muscles were covered in Tissue Tec and freezed 
immediately in - 150 °C cold Methyl-Butan. Subsequently, samples were shortly immersed in 
liquid nitrogen (-180 °C) and stored at the temperature of - 80 °C. 
 
2.10.2. Preparation of tissue sections 
 
For morphomethrical analysis, right and left adductor muscles were sectioned using 
the CM 3000 cryomicrotome (Leica, Germany). From every adductor, 6 sections were 
obtained; 2 from the upper part, 2 from the middle part and 2 from the lower part. The 
distances between the sections remained the same for every sample. Sections were 6 µm 
thick. 
 
2.10.3. Immunohistological staining 
 
After cutting, sections were fixed for 8 minutes in 4 % pFA. After this, they were 
washed twice for 5 minutes in PBS. Blocking solution containing 0.4 % glycin and 0.2 % 
bovine serum albumin (BSA) was used for 30 minutes to block unspecific binding sides.  
For smooth muscle cells staining, a fluorescein-5-isothiocyanate (FITC) -conjugated 
monoclonal antibody against α-smooth muscle actin (Serotec) was used at a 1 : 500 dilution in 
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blocking solution. Sections were incubated for one hour at 37 °C. Afterwards, slides were 
washed twice for 5 minutes in PBS. To stain endothelial cells, sections were incubated with 
tetramethylrhodamine isothiocyanate (TRITC) -BS1 lectin (Sigma) at a 1 : 30 dilution in PBS 
for 45 minutes at 37 °C. Samples were again washed twice. Nuclei were stained using 4’,6’-
diamidino-2-phenylindole dilactate (DAPI; Molecular Probes) at a 1 : 1000 dilution in PBS. 
Incubation was performed at room temperature for 15 minutes. After this, slides were washed 
three times with PBS. After adding Mowiol to the slides, sections were covered with cover 
slips. After drying, slides were stored at 4 °C until analysis was performed. 
 
Used solutions: 
4 % pFA: 
40 g PFA powder were added to 1000 ml PBS. While stirring, 2 or 3 NaOH crystals were 
added to the solution. After a complete dissolving of pFA, pH was adjusted to 7.4 and 
solution was stored at –20 °C until use. 
Blocking solution: 
0.4 g glycin and 0.2 g BSA were dissolved in 100 ml PBS. 
 
2.10.4.  Quantification of collateral artery growth 
 
From each section, all arteries were photographed under the fluorescent light using a 
DMRB Leica microscope (Germany) and a Leica DMLD digital camera. Large arteries like 
A. femoralis and A. profunda femoris were excluded. The outer vessel wall perimeter was 
marked and arterial vessel area was determined using the computer assisted planimetry 
software Image J.  
The vessel area of all arteries per muscle was counted to get the sum and the mean value. The 
sum reflected an increase in the number of collateral arteries which had grown after the 
ligature and the mean value described enlargement of the vascular perimeter. For every 
mouse, right-to-left ratio (R/L) was counted from sum and mean value, respectively. Finally, 
the mean R/L ratio was calculated for every experimental group of animals to compare the 
collateral vessel growth between controls and treated animals. Results were expressed as 
mean ± SEM.    
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2.11. Statistical analysis 
 
Values of each experimental group are presented as mean ± SEM. To calculate a 
statistical significance, an ANOVA test with a Bonferoni post hoc analysis was used. A value 
of p < 0.05 was considered as statistically significant.   
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3. Results 
 
3.1. Isolation of blood monocytes 
 
For injection into mice, monocytes were isolated from donor mouse blood using 
density gradient centrifugation. After staining with PE-conjugated murine monoclonal 
antibody against CD 11b, flow cytometric sorting of monocytes was performed. Monocytes 
subpopulation was identified according to their scatter characteristics and expression of CD 
11b and gated as shown in the following figure: 
 
 
 
Fig. 8.  Flow cytometry analysis of mouse leukocytes harvested from peripheral blood. 
Combination of regions B and D was used for sorting. A = Scatter light blot indicating 
measured blood cells. Cells from gate D reflecting monocytes are colored blue. B = CD11b 
expression of leukocyte subpopulations: Monocytes are gated, granulocytes (also CD11b 
positive) are distinguished from the monocytes by increased side scatter signal, lymphocytes 
(CD11b negative) are on the bottom (FL2Log: CD11b expression).  
 
Monocytes were sorted using advanced mode with high selectivity. In order to estimate purity 
of sorted cells, flow cytometry analysis was performed. Almost 98 % of isolated cells were 
monocytes as shown in the figure 9B. Cell viability as assessed by propidium iodide staining 
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was > 98 % (Fig. 10). Propidium iodide is a nuclear marker used for visualization of necrotic 
cells.  
 
 
Fig. 9.  Flow cytometry analysis of isolated cells. Regions B and D show percentage of CD 
11b positive cells from all isolated cells. 
 
 
 
Fig. 10.  Flow cytometry analysis of isolated monocytes after staining with propidium iodide. 
Region G shows the population of viable cells and region H shows dead cells. 
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3.2. Injection of isolated monocytes after femoral artery ligature of recipients 
 
3.2.1. Hemodynamic evaluations using Laser Doppler Imaging 
 
3.2.1.1. Pre- and post LDI measurements 
 
Pedal blood flow to mice feet was quantified using LDI. Pre-operative measurements 
were performed immediately before the femoral artery ligature and post-operative 
measurements immediately after the operation. There were no significant differences in pre-
operative and post-operative measurements between control group and the groups which had 
received injection of either 2 x 105 or 3 x 105 monocytes. 
 
Group Pre-LDI Post-LDI N 
Control 1.04 ± 0.04 0.07 ± 0.003 24 (19*) 
2x105 monocytes 1.01 ± 0.02 0.06 ± 0.006 11 
3x105 monocytes 1.01 ± 0.02 0.08 ± 0.01 7 (5**) 
 
Tab. 6.  Overview on pre- and post LDI measurements in experimental groups.   
* five animals were excluded at day 14 due to necrosis  
** two animals died during experiment 
 
3.2.1.2. LDI measurements at days 3, 7, 14 and 21 
 
In all three groups, blood flow recovery was observed starting on day 3. From this 
time point, the group treated with 2 x 105 monocytes showed a significant improved blood 
flow recovery through the complete experiment. The maximal difference was noticed at day 7 
(0.21 ± 0.02 in control mice vs. 0.30 ± 0.04 in 2 x 105 in monocyte-treated mice). 
Representative laser Doppler images of all groups are shown in figure 11. 
At day 14, five mice from the control group had to be excluded due to progredient necrosis in 
the foot, obviously as a result of an insufficient blood supply in the foot. At day 7, these mice 
showed the lowest blood flow recoveries. From day 14, LDI ratios of control mice were 
probably false higher. In the monocyte-treated animals, no necrosis was observed.  
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Fig. 11.  Representative laser Doppler images of mice distal hind limbs. Ligature of the 
femoral artery had been processed on the right leg. 
3. Results - 38 -
In order to evaluate if a correlation between the concentration of blood monocytes and 
the enhancement of arteriogenesis may exist, an increased number of monocytes (3 x 105 
cells) was injected in mice. Mice which had received 3 x 105 monocytes showed superior 
blood flow recovery compared to controls and the group which had received 2 x 105 
monocytes. 
However, a significant difference between the group with 2 x 105 monocytes and the group 
with 3 x 105 monocytes could not be detected, despite the presence of a marked trend towards 
a concentration-dependent improvement of blood flow recovery (fig. 12). 
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Fig. 12.  Blood flow recovery in the foot after femoral artery ligature as assessed by LDI 
before operation, immediately after and on the postoperative day 3, 7, 14 and 21.  
* = p<0.05; ** = p<0.01  
 
 
 
 
 
 
3. Results - 39 -
3.2.2. Hemoglobin oxygen saturation measurements 
 
3.2.2.1. Pre- and post measurements 
 
The pedal hemoglobin oxygen saturation (HOS) was measured in anaesthetized mice 
immediately before and after femoral artery ligature. There were no differences between 
control and monocyte-treated groups in pre-operative and post-operative measurements of 
oxygen saturation detectable (tab. 7).  
 
Group Pre-HOS Post-HOS 
control 1.00 ± 0.009 0.09 ± 0.006 
2x105 monocytes 1.00 ± 0.006 0.09 ± 0.007 
3x105 monocytes 1.00 ± 0.007 0.10 ± 0.10 
Tab. 7.  Pre- and post HOS measurements in experimental groups. 
 
3.2.2.2. Measurements at days 3, 7, 14 and 21 
 
Starting on day 3, significantly increased HOS was observed in monocyte-treated mice 
in comparison to controls. This difference was persistent during the complete observation 
period. HOS values between groups after receiving 2 x 105 monocytes and 3 x 105 monocytes 
did not differ as shown in figure 13. 
Monocyte-treated animals reached 90 % of the pre-operative values at the end of the 
observation period whereas control mice reached values only below 80 %.  
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Fig. 13.  Hemoglobin oxygen saturation measurements in control and monocyte-treated mice 
were performed before operation, immediately after and on post-operative days 3, 7, 14 and 
21. * = p<0.05; ** = p<0.01  
 
3.2.3. Histological findings 
 
3.2.3.1. Morphology of collateral vessels 
 
Adductor muscles of ligated and non-ligated hind limbs containing collateral arteries 
were harvested 21 days after femoral artery ligature. Cryosections were stained with primary 
antibodies (BS-1 lectin, anti-α-smooth muscle actin, DAPI) and analyzed.  
On the non-occluded side, pre-existing collateral arteries were characterized with smaller 
diameters and thinner vascular wall, in comparison to occluded side with grown collateral 
arteries. This was found in control group as well as in monocyte-treated groups (fig. 14). The 
left hind limb without occlusion served as control to ligated one and right-to-left ratios were 
calculated. 
Pre-existing collateral arteries did not distinguish morphologically from normal vessels and 
were identified according to the typical localization in the superficial layers of the adductor 
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muscle. Growing collateral arteries were mostly round shaped with a thick tunica media and 
inflammatory cells were surrounded in the close perivascular space. 
 
3.2.3.2. Injection of GFP-labeled monocytes in recipients 
 
In order to assess if transplanted monocytes were involved in the collateral artery 
growth after the femoral artery occlusion, GFP (green fluorescent protein) transgenic mice 
were used as blood donors for monocytes injection. Littermates of transgenic mice underwent 
femoral artery ligature and immediately received an injection of GFP-labeled monocytes. On 
day 3 after the operation, animals were sacrificed, perfusion fixed and adductor muscles were 
cryopreserved. Moreover, tissue from lungs, heart, kidneys, liver and spleen was collected. 
All samples were sectioned and analyzed under a fluorescent microscope (fig. 15). 
No GFP-positive cells were found in hearts, lungs and kidneys, some of them were detected in 
liver and many of them were found in spleen, which served as a positive control of monocyte 
transplantation (data not shown). Serial sections of adductor muscles were analyzed. In the 
non-occluded side, only few GFP-positive cells were found in the perivascular space.  
 
A 
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B 
Fig. 14.  Collateral arteries of a mouse using immunofluorescent staining (x 40): green for 
tunica media, red for endothelium and blue for nuclei. A: pre-existing collateral artery from 
left adductor muscle. B: remodelled collateral artery from right adductor muscle on day 21 
after right femoral artery ligature. 
 
 
Fig. 15.  Collateral artery of a mouse using confocal microscopy. A: in the right adductor, 
injected GFP-positive monocytes were observed in the lumen (L) of collateral arteries and in 
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the perivascular space. B: in the left adductor, only few GFP-positive monocytes were 
detected. 
 
 
Fig. 16.  Colocalization of GFP signal with F4/80 macrophage marker in the right adductor 
muscle using confocal microscopy. A shows GFP-positive cells and B shows specific F4/80 
immunofluorescence. Arrows point to injected monocytes/macrophages. L = lumen of 
collateral artery. 
 
After femoral artery ligature, a significantly increased number of GFP-positive cells was 
found in the lumen of growing collateral arteries and in the close perivascular space after 
transmigration through the vascular wall. 
Subsequently, sections were stained for PE-conjugated F4/80 macrophage marker (Caltag). 
GFP-positive cells in the perivascular space also expressed macrophage marker as shown in 
figure 16. These findings indicate that GFP+ monocytes which were injected via a tail vein 
were involved in the collateral artery growth. 
 
3.2.3.3. Morphometrical evaluations 
 
From every adductor muscle, 6 sections (2 from the proximal zone, 2 from the middle 
zone and 2 from the distal zone) were analyzed. Lumen of arteries was completely filled with 
a contrast agent, which helped to distinguish them from veins. In addition, they were mostly 
round shaped unlike veins which were collapsed and had a small lumen.  
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Mean and total arterial vessel area from every adductor muscle were calculated using Image J. 
R/L ratios were calculated for every mouse. Vessels on the occluded side had increased 
diameters and perimeters in control group as well as in monocytes-treated groups. Results are 
summarized in the following table: 
 
Experimental group Mean collateral area  
(R/L ratio) 
p Total collateral area 
(R/L ratio) 
p 
Controls 1.56 ± 0.07 - 1.88 ± 0.08 - 
2 x 105 Monocytes 1.77 ± 0.07 < 0.05* 2.37 ± 0.12 < 0.01* 
3 x 105 Monocytes 2.37 ± 0.11 < 0.01** 2.66 ± 0.12 n.s.** 
                                           
Tab. 8.  Morphometrical results. 
* against controls 
** against 2 x 105 monocytes                                             
 
 
 
 
3.3. Treatment with GM-CSF alone and in combination with monocyte injection in the 
mouse ischemic hind limb model 
 
3.3.1. Hemodynamic evaluations using Laser Doppler Imaging 
 
To investigate whether GM-CSF therapy may enhance arteriogenesis, mice received 
five intraperitoneal injections of rmGM-CSF (0.5 µg in 150 µl NaCl per day) starting two 
days before femoral artery ligature. No differences in pre- and post measurements were 
observed between any of the groups. After administration of GM-CSF alone, no difference in 
blood flow recovery compared to control group was detected (fig. 17). 
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Fig. 17.  Laser Doppler perfusion measurements of the foot in control, monocyte-treated  
animals, rmGM-CSF treated animals and combinations at several time points after femoral  
artery ligature. * = p<0.05; ** = p<0.01 
 
Importantly, no necrosis in GM-CSF-treated animals was observed in comparison to controls. 
Overview on necrosis index is shown in the following table. 
 
Experimental group Number of animals (N) Number of animals with 
necrosis 
controls 24 5 
i.p. GM-CSF 11 0 
 
Tab. 9.  Necrosis index.  
 
A combination of GM-CSF injections (1 µg in 150 µl NaCl per day) and monocyte injection 
was performed to investigate a potential additive or synergistic effect of GM-CSF on 
monocyte therapy. An increase in improvement of blood flow recovery compared to 2 x 105 
monocyte injections was detected in the combination group, but results did not reach 
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statistical significance. In our experiment, the group of animals treated with GM-CSF 
injections in combination with 3 x 105 monocyte injections showed the best blood flow 
recovery.  
 
3.3.2. Hemoglobin oxygen saturation measurements 
 
Pedal oxygen saturation of hemoglobin was measured in anaesthetized animals 
directly before operation, immediately after and on post-operative days 3, 7, 14 and 21. All 
pre-operative measurements did not differ and R/L ratios were about 1. Directly after the 
operation, HOS ratios dropped to 10 % of the starting point. From this time point on, R/L 
ratios of HOS continuously improved, however they did not reach pre-operative values at the 
end of the observation period. Mice which were treated with GM-CSF injections solely, did 
not differ in hemoglobin oxygen saturation values from control mice except from day 3 (fig. 
18). Interestingly, mice treated with 2 x 105 monocytes and GM-CSF or 3 x 105 monocytes 
and GM-CSF did not differ in hemoglobin oxygen saturation values from mice which were 
treated either with 2 x 105 monocytes or 3 x 105 monocytes except from day 3.  
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Fig. 18.  Hemoglobin oxygen saturation measurements during the observation period in 
controls, in mice after monocyte injections (2 or 3 x 105 cells), in i.p. GM-CSF-treated mice 
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and in mice which received a combination of GM-CSF and monocytes. * = p<0.05; ** = 
p<0.01 
 
3.3.3. Morphometrical findings 
 
Adductor muscles were sectioned and stained for morphometrical analysis. Mice 
which were treated with intraperitoneal injections of rmGM-CSF had bigger vessel diameters 
and perimeters in comparison to controls. However, these differences were not statistical 
different which is in accordance with laser Doppler measurements (Tab. 10).  
 
Experimental group Mean 
collateral area 
(R/L ratio) 
p Total 
collateral area 
(R/L ratio) 
p 
i.p. GM-CSF 1.62 ± 0.06 n.s.* 1.91 ± 0.11 n.s.* 
2 x 105 Monocytes + i.p. GM-CSF 2.29 ± 0.13 < 0.01** 2.66 ± 0.19 n.s.** 
3 x 105 Monocytes + i.p. GM-CSF 2.96 ± 0.26 < 0.05*** 3.32 ± 0.14 < 0.01***
 
* against controls           ** against 2 x 105 monocytes           *** against 3 x 105 monocytes 
Tab. 10.  Morphometrical results.  
 
Morphometrical analysis of collateral arteries from mice treated with combination of i.p. GM-
CSF and 2 x 105 monocytes revealed that the vessel diameters were significantly larger in 
comparison to mice which received only 2 x 105 monocytes. Mice treated with combination of 
i.p. GM-CSF and 3 x 105 monocytes had even larger collateral arteries and the difference was 
statistical significant in comparison to mice treated only with 3 x 105 monocytes. Moreover, 
total collateral vessel area was significantly increased in comparison to 3 x 105 monocytes-
treated mice. These results suggest that a combination of GM-CSF treatment with monocyte 
injections was effective. Results are summarized in following diagrams: 
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Fig. 19.  Overview on mean collateral vessel areas in experimental groups. Largest mean 
collateral vessel area was observed in the group treated with combination of 3 x 105 monocyte 
injection and i.p. GM-CSF. * = p<0.05; ** = p<0.01 
 
 
 
Fig. 20.  Overview on total collateral vessel areas in experimental groups. Results correspond 
with mean collateral vessel areas. * = p<0.05; ** = p<0.01 
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3.4. Effect of Cicaprost and GM-CSF primed monocytes on blood flow recovery after 
femoral artery ligature 
 
3.4.1. Hemodynamic evaluations 
 
In order to test if the arteriogenic potential of monocytes may be enhanced by priming 
of isolated monocytes by incubation with a synthetic prostacyclin (Cicaprost, Schering, 
Germany), an additional experiment was performed. After 2 hours incubation with 100 ng/ml 
of Cicaprost under sterile conditions at 37 °C and 5 % CO2, 2 x 105 monocytes were injected 
into a tail vein. Furthermore, we tested if an incubation of isolated monocytes with 200 ng/ml 
of rmGM-CSF for 3 hours might enhance the arteriogenesis. After incubation, conditioned 
monocytes were injected after femoral artery ligature into a tail vein of recipient. 
Pre- and post measurements were performed before and directly after the operation. No 
differences in pre- and post measurements in comparison to control mice were noticed (fig. 
21). 
Mice treated with Cicaprost-incubated monocytes showed significantly higher blood flow on 
day 7 and 14 in comparison to controls. At the day 3, R/L ratio was comparable with control 
group. However, there was any improvement in blood flow recovery in comparison to mice 
treated only with 2 x 105 monocyte injection. On the contrary, there was a delay on the day 3. 
Mice treated with GM-CSF primed monocytes did not show any improvement of blood flow 
recovery comparing to controls. Two mice from this group were excluded because of severe 
foot necrosis. Blood flow ratios were slightly below the control group suggesting that 
incubation with rmGM-CSF may have a negative effect on the arteriogenic properties of 
injected monocytes.  
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Fig. 21.  Laser Doppler perfusion measurements of the foot in control, monocyte-treated mice,  
            and mice treated with monocytes incubated with either Cicaprost or GM-CSF at several time 
points after femoral artery ligature. * = p<0.05 
 
3.4.2. Hemoglobin oxygen saturation measurements 
 
Pedal oxygen saturation of hemoglobin was measured in anaesthetized animals 
directly before operation, immediately after and on post-operative days 3, 7, 14 and 21. All 
pre- and post measurements in treated animals did not differ from controls. Mice which 
received an injection of monocytes after being incubated with GM-CSF had comparable 
hemoglobin oxygen saturation values with controls. This was in line with laser Doppler 
Imaging data. Mice treated with monocytes after being incubated with Cicaprost had 
significantly better hemoglobin oxygen saturation values than controls starting on day 7. 
However, similarly to laser Doppler measurements, there was a delay on day 3 in comparison 
with 2 x 105 monocyte-treated group. In general, these HOS measurements confirm laser 
Doppler measurements and show that incubation of monocytes with either Cicaprost or GM-
CSF did not support the arteriogenesis.  
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Fig. 22.  Hemoglobin oxygen saturation measurements in control, monocyte-treated mice and 
mice treated with monocytes incubated with GM-CSF or Cicaprost at certain time points.* = 
p<0.05; ** = p<0.01 
 
3.4.3. Histological evaluations 
 
Adductor muscles were harvested on day 21 and stained for morphometrical analysis. 
Mice treated with 2 x 105 monocytes primed with GM-CSF had comparable mean arterial 
vessel area to control group. On the other hand, total arterial vessel area dropped down almost 
significantly. Again a negative effect of incubation with GM-CSF can be assumed. 
Mice treated with 2 x 105 monocytes incubated with Cicaprost had the same mean arterial 
vessel area as mice which have received injection of 2 x 105 monocytes. However, total 
arterial area did not reach the values of 2 x 105 monocyte-treated mice. Results are 
summarized in table 11. 
 
 
 
3. Results - 52 -
Experimental group Mean collateral 
area ( R/L ratio) 
p Total collateral 
area (R/L ratio) 
p 
2 x 105 Monocytes incubated 
with GM-CSF 
1.62 ± 0.07 n.s.* 1.57 ± 0.06 n.s.* 
2 x 105 Monocytes incubated 
with Cicaprost 
1.77 ± 0.09 n.s.* 2.26 ± 0.13 < 0.05* 
* against controls               
Tab. 11.  Morphometrical results.   
 
3.5. Angiography 
 
Post-mortem angiograms were performed 21 days after right femoral artery ligature. 
On the non-occluded sides, in every experimental group of animals, only thin and few pre-
existing collaterals were found. Larger corkscrew-patterned vessels were identified in all 
animals on the occluded side. Although the number of visible collaterals was not quantified, 
marked differences between controls and monocyte-treated animals were noticed. Following 
representative angiograms show the differences in the collateral artery development on the 
occluded sides between experimental groups.  
 
   
A                                                                          B 
Fig. 23.  Representative post-mortem angiograms of mouse hind limbs from a control group 
(no treatment). A: left B: right hind limb  
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In the control group of animals, only few collateral arteries have been developed. This 
corresponded well with the poor functional recovery of the occluded hind limb. Treatment 
with monocytes or combination with monocytes and GM-CSF caused except of better 
functional recovery of occluded hind limbs high density of well developed collateral network 
(Fig. 24; 25). 
 
   
A                                                                         B 
Fig. 24.  Representative post-mortem angiograms of mouse hind limb vessels after monocyte-
Cicaprost treatment. A: left B: right hind limb  
   
A                                                                          B         
Fig. 25.  Representative post-mortem angiograms of mouse hind limb vessels after monocyte 
and GM-CSF combination treatment. A: left B: right hind limb  
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3.6. Active foot movement 
 
Active foot movement was measured from the day 3 after the femoral artery ligature. 
In the control group, 5 from 24 mice have developed necrosis in the foot and were excluded 
from the study. Only in the control group has necrosis occurred. Mice which have received 
monocytes injection have recovered quicker than control mice. At the end of the measured 
period all the mice have reached almost complete recovery. The biggest differences in the 
recovery were noticed at the day 3. There were no significant differences between groups 
treated with monocytes and monocyte – GM-CSF combinations (Fig. 26). Between controls 
and monocyte–treated animals, there was a significant difference on days 3, 7 and 14 as 
shown in the following table:  
 
Day 3 7 14 21 
Controls 1.44 ± 0.10 1.88 ± 0.12 2.42 ± 0.11 3.34 ± 0.10 
2 x 105 Monocytes  2.09 ± 0.17 2.59 ± 0.16 3.23 ± 0.25 3.59 ± 0.16 
t-test p < 0.01 p < 0.01 p < 0.5 n. s. 
 
Tab. 12.  Active foot movement score between control and monocyte-treated group. 
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Fig. 26.  Active foot movement score measurements performed on days 3, 7, 14 and 21 after 
the femoral artery ligature. * = p<0.05; ** = p<0.01.
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4. Discussion 
 
4.1. Introduction 
 
Arteriogenesis was previously described as a process adaptive to arterial occlusion 
accompanied by growth of collateral arteries. This is in distinction to angiogenesis which is a 
de novo formation of capillary networks 21. Positive remodeling of pre-existing collaterals is 
triggered by elevated fluid shear stress 63 and regulated by growth factors and cytokines which 
are secreted by activated endothelial cells, smooth muscle cells and by invading inflammatory 
cells, in particular monocytes and T-lymphocytes. 
The objective of this study was to find out if monocytes can be used as cellular 
therapeutics in the treatment of cardiovascular occlusive diseases. Moreover, we tried to 
answer the question whether the arteriogenic potential of monocytes can be enhanced by 
priming with various substances. Furthermore, therapeutic implications of the use of GM-CSF 
as a potential growth factor for the treatment of peripheral occlusive diseases were tested. For 
this reason, the mouse ischemic hind limb model was used to simulate peripheral arterial 
occlusive disease. 
Mechanisms by which monocytes contribute to collateral vessel growth have been previously 
described. The activated collateral endothelium expresses adhesion molecules (ICAM-1 and 
ICAM-2, VCAM-1) which are involved in adhesion and accumulation of blood monocytes. 
Activated monocytes bind to endothelial cell adhesion molecules via their integrin receptors 
LFA-1 and Mac-1 64 and start to produce growth factors and matrix-metalloproteinases that 
facilitate their penetration of the intima. After entering the collateral vessel wall, monocytes 
differentiate into macrophages which then produce cytokines involved in vascular cell 
proliferation (e.g. TNF-α, bFGF and TGF-β). 
 
4.2. Animal model 
 
In numerous studies an animal model of acute hind limb ischemia was used to study 
arteriogenic mechanisms. Several variants of this model have been developed on different 
species like mouse, rat, dog, rabbit65, 66, 20, 67.  
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A mouse model of arteriogenesis was first demonstrated by Couffinhal et al. 1998. The 
authors created unilateral hind limb ischemia by ligature of the proximal end of the femoral 
artery and the distal portion of the saphenous artery. Afterwards, the femoral artery including 
accompanying branches was excised. This extensive surgical intervention was performed in 
mice with the C57BL/6 genetic background that can tolerate ischemia well. This model is not 
suitable for the BALB/c strain of mice, as their genetically determined collateral network is 
poor 68 and they tend to develop foot necrosis more frequently (own observation). Because of 
strain differences in the extent and speed of blood flow recovery after the experimental 
arterial occlusion, it is reasonable to use BALB/c mice for studies in which the tested 
substances are expected to accelerate arteriogenesis. 
The mouse model of hind limb ischemia was improved and modified by several research 
groups. The model as described in this dissertation was employed in the Max-Planck-Institut 
in Bad Nauheim. In distinction to previous mouse models, the femoral artery was ligated 
distally to the deep femoral artery and proximally to the branching of the popliteal artery. This 
surgical intervention allowed a development and growth of anastomoses between deep 
femoral artery and saphenous artery without excessive necrosis and self-amputation. 
Compared to other models of arteriogenesis, i.e. in rabbits, pigs and dogs, the mouse 
model has several advantages. The main advantage compared to bigger animals is in the 
ability to operate and hemodynamically evaluate a set of mice sufficient for meeting statistical 
requirements per one day, due to the non-invasive blood flow measurements and easier 
manipulation of animals. Moreover, transgenic mice can be used to study the influence of 
disrupted gene expression and gene overexpression on physiological functions. Small animals 
are also suitable to test growth factors due to lower dosages and lower expenses. 
However, a disadvantage of the mouse model is the impossibility to directly measure 
collateral conductance because of the small vessel parameters in mice. Instead, substitutional 
methods like blood flow recovery in the distal limb have to be used. Moreover, similarly to 
other animals, mice may have considerable interindividual differences in blood flow recovery 
in response to acute ischemia which can lead to increased variations in hemodynamical 
measurements.  
In small animals like mice and rats, only few methods of in vivo blood flow 
measurements are available. The principle of microsphere technique is that regional blood 
flow to an organ is proportional to the number of microspheres trapped in that organ. 
Radioactive microsphere technique, previously reported to be a “gold standard” method for 
regional blood flow measurements, allows to measure blood flow in regions where the use of 
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probes or sensors is impractical, or where invasive surgical procedures may compromise the 
animal 69. However, this method is depending upon correct placement of the reference blood-
withdrawal catheter. The main disadvantage of microsphere technique, compared to flow 
probe methods, is in measuring of blood flow at a single time point at the termination of a 
study without the possibility of a continuous monitoring. In addition, microspheres are 
trapped in the capillaries and due to the small size of mouse capillaries they may embolize 
larger vessels and lead to the false interpretation of results. Furthermore, fluorescence and 
colored microspheres are only detectable after their isolation from tissues using complete 
tissue digestion 70. Hence, further morphological analysis of tissue is impossible.  
The laser Doppler technique for blood flow measurement is characterized as a flow probe 
method 69 which was employed to determine relative changes in regional blood flow. This 
technique allows the assessment of blood-vessel function at both, microcirculatory and 
macrocirculatory levels, depending on the penetration into the tissue. For blood flow recovery 
measurements in mice, the limited penetration of laser light was sufficient to obtain 
meaningful results. 
The accurate application of LDI requires that several criteria for the measurement have to be 
respected. To avoid errors associated with temporary changes in vasomotion of measured 
vessels, mice have to be placed in a climatized chamber under standardized temperature 
immediately before and during every measurement. According to our observations, pre-
warming of mice at 37 °C for five minutes is necessary to standardize the measuring 
conditions. Exact placement of mice on the pad with parallelly oriented hind limbs is required 
to achieve an equal penetration of laser light into both feet. Furthermore, in order to reach a 
higher resolution, the scanned area has to include only tissue or region of interest. In contrast, 
others have included complete distal parts of the body with losses in resolution 71. 
The main disadvantage of LDI method is that it does not determine an absolute blood flow in 
a particular vessel. Despite of that, the laser Doppler technique is suitable for blood flow 
measurements in small experimental animals, because the blood vessels do not have to be 
isolated and exposed.  
Very recently, a method based on magnetic resonance imaging (MRI) for blood flow 
measurements in mice has been developed 72. The advantages of this method are the in vivo 
visualization of collateral arteries in the range of 100 µm without using a contrast agent 
injection. Moreover, an improved MRI method termed “Time-of-Flight” imaging allows for 
assessment of many mice in a short time period and the animals can be repetitively studied. 
This method provides a quantitative measurement of blood flow distally to the arterial 
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occlusion and shows the redistribution of the blood flow. Hence, in the future, improved 
assessment of data in the mouse model of hind limb ischemia can be used.  
 
4.3. Morphometrical analysis 
 
Histological analysis of adductor muscles was performed using conventional 
fluorescence microscopy. Vessels were filled with a bismuth-based contrast agent and stained 
with endothelial and smooth muscle cell markers. Arteries of the collateral region with the 
vessel area smaller than 100 µm2 as well as branches of the deep femoral artery were not 
counted. The mean collateral vessel area was calculated to investigate whether the 
remodelation of collateral arteries of mice treated with monocytes was more extensive than of 
those of non-treated mice. 
In this study, morphometrical analysis was performed as previously described by Heil et al. 36. 
The advantage was the use of cryosections, which were easy to cut and allowed the use of 
fluorescent-labeled antibodies. On the other hand, it was not possible to measure the internal 
vessel diameters and vascular wall area because of the contrast agent filling the arteries. 
Some other groups (Scholz et al. 73) studied Epon-embedded semi-thin sections of two 
superficial collateral arteries stained with toluidin blue under light microscopy. Internal vessel 
diameters and the arterial wall area were evaluated. This method enables to measure vascular 
wall area by subtracting the luminal area from the area under the external border of the tunica 
media in order to differentiate between vessel dilatation and growth.  
In our tissue perfusion model, a specific concentration of adenosine was added to avoid 
interindividual differences in vasodilation. Compared to previous studies where only two 
superficial collateral arteries per muscle were analyzed, we improved this method by 
including all collateral vessels in adductor muscles for morphometrical analysis, because all 
collateral vessels contribute to blood supply. 
 
4.4. Active foot movement measurements 
 
The active foot movement by operated mice was used as a supplementary 
measurement to obtain a functional parameter. However, it is influenced by the subjective 
evaluation of the evaluating person. Four score grades, as suggested and used before, seem to 
be insufficient to describe slight improvements and differences in using the ischemic leg.  
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In summary, we found a significant improvement in active foot movement in mice treated 
either with monocytes (2 x 105 or 3 x 105 cells) or with a combination of monocytes and GM-
CSF compared to control mice, except from day 21 when no differences were detected. As 
five control mice had to be excluded on day 14, active foot movement values on day 14 and 
21 were probably falsely higher in this group. In monocyte-treated groups and combination 
groups, the functional recovery of the hind limbs after femoral occlusion was very good and 
mice did not differ in active foot movement score. At the end of the observation period, these 
mice showed almost 100 % functional recovery of the occluded leg, which means that 
movement with the operated hind limb was unrestricted. 
 
4.5. Angiographic evaluations 
 
Angiographic measurements were performed post-tmortem via abdominal aorta 
cannulation on day 21 after the femoral artery ligature using a bismuth-based contrast agent. 
In the occluded hind limbs of control mice, only few collateral arteries were detected. In mice 
treated with monocytes (2 x 105 cells) or Cicaprost-incubated monocytes, high density of well 
developed collateral arteries could be identified compared to controls. The most developed 
collaterals were found in the groups treated with a combination of GM-CSF and monocyte 
injections. 
As mice arteries are very small, it is impossible to detect differences in size by angiography. 
However, this method offers good qualitative evaluation of collateral vessel growth by 
comparing between experimental groups of animals.  
 
4.6. Injection of isolated monocytes after femoral artery ligature 
 
Monocytes were injected as a bolus directly after femoral artery ligature. Hence, 
monocytes were distributed through the circulation system into all tissues and not all injected 
cells contributed to the growth process after local accumulation. A concentration of 2 x 105 
monocytes in 150 µl NaCl already had a significantly positive effect on blood flow recovery. 
Injection of 3 x 105 monocytes resulted in superior blood perfusion values of the foot. The 
highest well tolerated dose of monocytes was not established, however, two mice died several 
days after receiving an injection of 3 x 105 monocytes. Hence, we suppose that the highest 
tolerated single dose might be close to 3 x 105 monocytes. Application of 3 x 105 monocytes 
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did not show a significant improvement of blood flow recovery compared to dose of 2 x 105 
monocytes although a distinct trend toward a further increase in blood flow recovery in mice 
which received 3 x 105 monocytes was observed. As the isolation of monocytes from mouse 
peripheral blood is very animal consuming and not trivial, we did not increase the number of 
animals in this experimental group (n=7). It can be speculated that the maximal effect in the 
BALB/c strain of mice after the monocyte injection was already achieved by injection of 3 x 
105 monocytes. Furthermore, one can assume that several injections at different time points 
after femoral artery ligature could continuously increase the pool of monocytes and further 
enhance the blood flow recovery. 
Hemoglobin oxygen saturation measurements showed no differences between the group, 
which received 2 x 105 monocytes and the group, which received 3 x 105 monocytes. This 
was unlike LDI measurements, where the application of 3 x 105 monocytes showed a distinct 
trend toward an increase in blood flow recovery. It can be assumed that mice treated with 2 x 
105 monocytes already reached the maximum of hemoglobin oxygen saturation recovery 
measured under narcosis in the BALB/c strain of mice. 
Our morphometrical results show that the diameters of collateral arteries and the collateral 
vessel area in the hind limb after femoral artery ligature in mice treated with 2 x 105 
monocytes were significantly larger in comparison to non-treated mice [R/L ratio of mean 
collateral vessel area in 2 x 105 monocyte-treated (1.77 ± 0.09) vs. control mice (1.56 ± 0.07), 
p < 0.05]. Moreover, collateral vessel area R/L ratio in mice treated with 3 x 105 monocytes 
(2.37 ± 0.11) was significantly higher (p < 0.01) compared to mice treated with 2 x 105 
monocytes. This result confirmed a trend from LDI measurements indicating toward 
increased blood flow recovery in mice treated with 3 x 105 monocytes. Hence, we conclude 
that the higher concentration of injected monocytes had indeed a positive effect on collateral 
artery growth. 
Additionally, total collateral vessel area in mice which received 2 x 105 monocytes was 
significantly increased in comparison to non-treated mice (2.26 ± 0.13 vs.1.88 ± 0.08; p < 
0.01). In mice treated with 3 x 105 monocytes, further enlargement of total collateral vessel 
area was detected (2.66 ± 0.19), although the difference did not reach statistical significance 
compared to mice treated with 2 x 105 monocytes. A possible explanation of this result can be 
derived from physiological mechanisms of the collateral blood vessel development. As 
previously described, large collateral arteries are maintained in order to conduct bulk flow, 
while smaller collateral vessels regress. Few large arteries are more effective for blood 
perfusion than many small vessels as can be affiliated from the Hagen-Poiseuille’s law. This 
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can also explain why the collateral vessel area in mice treated with 3 x 105 monocytes did not 
increase significantly despite markedly enlarged vessel diameters. 
 
Our results of monocyte-treatment after experimental artery occlusion correlate well 
with a previous study in our group, 19 in which the concentration of blood monocytes in mice 
and rabbits was manipulated by an injection of 5-fluorouracil. After femoral artery ligature, an 
increased collateral conductance and an increased number of visible collaterals in rabbits was 
observed during the rebound phase after monocyte depletion. In mice, pedal blood flow 
measured by laser Doppler was enhanced between days 7 and 21, if the femoral artery was 
ligated during the rebound period. In contrast, ligature during the depletion phase of 
monocytes resulted in impaired blood flow recovery. 
The importance of monocytes in collateral artery growth was also reported in previous studies 
32,74,33,19,75 , in which it was observed that circulating blood monocytes adhere to the vascular 
wall during collateral vessel growth. Moreover, accumulated monocytes were positively 
stained for vascular growth factors (bFGF and TNF-α) which are necessary for collateral 
vessel growth 33. These findings suggest that monocytes contribute to arteriogenesis as 
producers of growth stimulating substances, similarly to bone marrow stem cells which were 
reported to act through a paracrine mechanism by producing cytokines “cytokine factories” 76,  
Other studies investigated the molecular pathway of monocyte attraction and activation 
35,77,36. Monocyte chemoattractant protein-1 (MCP-1) was previously described to be 
upregulated by shear stress in collateral arteries in vitro. In the rabbit ischemic hind limb 
model, after local delivery of MCP-1 into the proximal branches of femoral artery via osmotic 
minipump, markedly increased collateral conductance was detected in comparison to rabbits, 
which received PBS. 
In a mouse model of acute inflammation 77, resident tissue peritoneal macrophages were 
diminished using thioglycolate injection. In both, control and CC-chemokine receptor-2 
(CCR2) knock out (k.o.) mice, the number of resident macrophages rapidly decreased as 
detected 4 hours after the injection. Within 24 hours, the number of peritoneal macrophages in 
the control group reached two times basal levels in contrast to CCR2 k.o. mice which did not 
even reach basal values. These results demonstrate that CCR2 receptor, which is the exclusive 
MCP-1 receptor in mice, is essential for monocyte/macrophage migration.  
In our own study, we used CCR2 k.o. mice in the ischemic hind limb model to determine, 
whether the MCP-1-CCR2 signaling pathway is involved in collateral artery growth 36. We 
performed a chemotaxis assay which revealed almost abolished mononuclear cell migration 
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towards MCP-1 in the blood of CCR2 k.o. mice. Additionally, blood flow recovery in 
BALB/c background of CCR2 k.o. mice as assessed by LDI was remarkably impaired in 
comparison to control mice. Moreover, the number of monocytes/macrophages around 
collateral arteries of CCR2 k.o. mice on day 4 after femoral artery ligature was significantly 
reduced in comparison to wild-type mice. Hence, these data also suggest that blood 
monocytes are necessary in early stages of collateral vessel growth.                    
 
4.7. Injection of GFP-labeled monocytes 
 
To obtain further evidence for the pivotal role of circulating monocytes and evaluate 
the role of resident macrophages for arteriogenesis, we injected GFP-labeled monocytes into a 
tail vein in order to track the way of injected monocytes in recipients. 
For this reason, GFP-transgenic mice were used as blood donors. This transgenic line shows 
ubiquitously expression of eGFP except erythrocytes and hair follicle cells 78. Mononuclear 
cells from these transgenic mice were harvested via density gradient centrifugation of 
peripheral blood, stained with PE-conjugated murine monoclonal antibody against CD11b and 
isolated using a cell sorter according to their scatter characteristics and their CD 11b 
expression. GFP-monocytes were injected into a tail vein after femoral artery ligature of 
recipients. Animals were sacrificed on day 3 after the ligature, which was previously reported 
as a day of maximal monocyte/macrophage accumulation during the collateral artery growth 
33. 
Many GFP-positive cells were found in the spleen which served as a positive control of 
proper monocyte injection. Some GFP-positive monocytes were found in the liver and no 
GFP-labeled cells were found in the hearts, lungs, peritoneum and kidneys. In non-ligated 
hind limb adductor muscles, a marginal number of GFP-positive cells was detected as well 
which might be a consequence of the participation of the injected cells in physiological blood 
circulation. In ligated hind limb adductor muscles, a significantly increased number of GFP-
labeled cells was observed in the collateral vessel region. This provides evidence that injected 
monocytes circulated in the blood, were attracted by collateral endothelium and migrated 
through the vessel wall into collateral artery surrounding tissues. Subsequent staining for 
specific macrophage marker F4/80 showed that accumulated GFP-labeled monocytes also 
expressed a specific macrophage marker and presumably secreted vascular growth factors. 
        However, some groups proposed that resident tissue macrophages rather than circulating 
blood cells play the most important role in arteriogenesis 79, 80. In the study of Khmelewski, 
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Becker et al. 2004, fluorescence(CMFDA)-labeled blood cells were injected into the femoral 
artery of rats after its occlusion. The labeled cells included all leukocyte subpopulations and 
thrombocytes. It should be considered that the incubation of cells with a fluorescent cell 
membrane affecting marker might influence their arteriogenic activity, as no labeled cells 
were detected around collateral vessels. Moreover, no control rats were used to compare the 
collateral artery growth in non-treated and treated animals. In summary, the data presented by 
Khmelewski et al. are not very convincing because of these methodological shortcomings.  
Our results are in line with another study of a unilateral hind limb ischemia model in rats 81. 
The authors injected fluorescence-labeled human peripheral blood cells (mononuclear cells + 
platelets or mononuclear cells + platelets + polymorphonuclear leukocytes or 
polymorphonuclear leukocytes alone or platelets alone) intramuscularly into ischemic limbs 
of athymic rats after femoral artery ligature. LDI measurements revealed significantly 
increased blood flow in rats which received mononuclear cells + platelets in comparison to 
control rats, which received human umbilical vein endothelial cells (HUVEC). Interestingly, 
addition of polymorphonuclear leukocytes to mononuclear cells and platelets significantly 
attenuated blood flow compared to treatment with mononuclear cells and platelets alone. 
Infusion of platelets alone had a positive influence on blood flow recovery although the R/L 
ratios were markedly below those of the group treated with mononuclear cells + platelets. 
Infusion of polymorphonuclear leukocytes alone did not have any influence on blood flow 
recovery. In conclusion, mononuclear cells and platelets were involved in the collateral artery 
growth, whereas polymorphonuclear leukocytes did not have any effect on blood flow 
recovery. Furthermore, Iba et al. 79 proved that mononuclear cells and platelets migrated 
towards arterioles, accumulated in the perivascular region and secreted VEGF, bFGF, PDGF-
AB and TGF-β. These findings suggest that monocytes contribute to the collateral vessel 
growth by a paracrine mechanism.  
The importance of monocytes in the early stages of remodeling was confirmed after 
their experimental depletion from circulation using cytotoxic bisphosphonates 75. It was 
followed by a complete abolishment of arteriogenesis in the rabbit ischemic hind limb model.  
The role of other circulating cells in arteriogenesis has yet not been well elucidated. However, 
several kinds of blood cells seem to be involved in the growth process. After migration of 
their precursors from the blood stream, mast cells were found in a widened adventitia of 43 
collateral vessel walls, secreting MMP-9 82. Moreover, mast cells were reported to produce 
VEGF, bFGF, TGF-β, TNF-α, IL-8 and other cytokines which stimulate cells (e.g. fibroblasts, 
macrophages) to secrete angiogenic factors 83. Mast cells may contribute to arteriogenesis also 
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by chemotactic recruitment of monocytes/macrophages, lymphocytes and by activation of 
platelets which in turn could produce angiogenic factors. 
The role of T lymphocytes in arteriogenesis was tested in CD4 gene-deficient mice in which 
the development of CD8+ T cells and myeloid components was unaltered, whereas the 
number of CD4+ T cells was markedly reduced 84. After creation of unilateral hind limb 
ischemia, CD4 gene-deficient mice showed a significant reduction in collateral artery density 
in the thigh of the operated hind limb in comparison to control mice. Furthermore, a severe 
reduction in blood flow recovery in CD4 knockout mice was observed. Moreover, the 
suggested mediating mechanism of reduced collateral development was probably due to the 
decreased monocyte/macrophage recruitment. 
Other circulating cells which contribute to postnatal neovascularization are endothelial 
progenitor cells (EPC) which originate from CD34+ mononuclear cells 41. EPC mostly 
express monocyte/macrophage markers (CD14, Mac-1, CD11c) and lower percentage of cells 
express endothelial cell marker (VE-cadherin) and progenitor cell marker (AC133, c-kit) 85. 
They contribute to collateral vessel formation by secretion of growth factors like VEGF, 
hepatocyte growth factor and GM-CSF rather than by proliferation and differentiation into 
endothelial cells. EPC were found in increased concentration in peripheral blood after acute 
myocardial infarction 86 or after stimulation with cytokines.  
Studies on bone marrow stem cells and their contribution to tissue repair show contradictory 
conclusions. On the one hand, bone marrow cells were reported to be incorporated into tissue 
of injured organs (e.g. infarcted myocardium) and to differentiate into tissue-specific cells 
after their transplantation into ischemic myocardium 87,88 or ischemic hind limb tissue 89. 
However, the mechanism by which these cells contribute to improved tissue perfusion has not 
been well elucidated. On the other hand, recent reports show that bone marrow-derived cells 
do not incorporate into the adult growing vasculature but accumulate in the area of growing 
vessels and produce a cocktail of growth factors and chemokines 47. 
 
 
4.8. Combination of monocyte injection with GM-CSF treatment 
 
A very important observation in almost all experimental settings of arteriogenesis is 
the lack of a complete recovery of physiological blood flow. This raises the idea to condition 
monocytes prior to injection for further stimulation of arteriogenesis. We tested the potential 
therapeutic efficacy of a combination of monocytic treatment with GM-CSF administration. 
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GM-CSF was previously reported to be a growth factor prolonging the life span of monocytes 
and their rate of differentiation 56. 
In one approach, mice received 5 injections of rmGM-CSF starting two days before femoral 
artery ligature. On the third day, the femoral artery was occluded and monocytes were 
injected into a tail vein. LDI measurements revealed improvement in blood flow recovery 
starting on day 3 after the operation. Although a significant difference compared to mice 
which received 2 x 105 monocytes alone was not detected, a prominent trend toward a further 
enhancement in blood flow recovery was detected. A similar effect was noticed when a higher 
concentration of monocytes (3 x 105 cells) was combined with rmGM-CSF injections as 
described before. Blood flow recovery was improved in comparison to mice, which received 3 
x 105 monocytes alone, but did not reach statistical significance.  
Hemoglobin oxygen saturation (HOS) measurements of mice treated with a combination of 
rmGM-CSF and monocyte injection showed a significant improvement compared to controls. 
However, it seemed that mice treated with 2 x 105 monocytes already reached the maximal 
HOS values. That may explain why no further increase in HOS in mice which received a 
combination of either 2 x 105 monocytes or 3 x 105 monocytes and GM-CSF was observed. 
Morphometrical analysis showed that collateral diameters and perimeters of the combination 
group (2 x 105 monocytes + GM-CSF) increased significantly compared to mice treated with 
2 x 105 monocytes alone. Similar results were obtained from mice treated with 3 x 105 
monocytes + GM-CSF, in which the mean collateral area was significantly larger than in mice 
treated with 3 x 105 monocytes alone. Moreover, the total collateral vessel area also was 
significantly larger. 
 
4.9. Application of GM-CSF alone in the mouse ischemic hind limb model 
 
In the second approach, mice received subcutaneous injections of GM-CSF to test if 
GM-CSF application alone can enhance the arteriogenesis. GM-CSF was previously 
described to be a potent arteriogenic growth factor 56, 55, 90. After the local delivery of GM-
CSF into the proximal stump of occluded femoral artery in rabbits via an osmotic minipump, 
an increased number and size of collateral arteries were detected on post-mortem angiograms 
as well as an increased collateral conductance 56. The arteriogenic potential of GM-CSF was 
also tested in a rat cerebral hypoperfusion model 90. After the occlusion of both vertebral and 
the left carotid artery in rats, GM-CSF or saline was injected into the non-occluded carotid 
artery and subcutaneous injections of GM-CSF or saline were administered every second day 
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for one week. GM-CSF treatment had no influence on the arterial architecture of the dorsal 
brain surface and on the diameters of Heubner’s anastomoses in comparison to saline-treated 
rats. An increased diameter of the posterior cerebral artery (PCA) in saline- and GM-CSF-
treated animals after one week (260 µm vs. 320 µm) was measured and both diameters were 
significantly larger than in non-operated animals without any ischemic events. It is not clear if 
the increase of the PCA diameter in GM-CSF-treated animals was also significant compared 
to saline-treated animals as this would be the result which may have shown the effectiveness 
of the GM-CSF treatment. However, an important question is whether these measurements 
really refer to arteriogenesis (development of collaterals from pre-existing arteriolar 
connections), considering that the PCA is an important supplying artery fully developed in 
healthy non-ischemic brain. Alternatively, this could be a vasodilation effect or an adaptation 
to altered flow conditions as can be frequently observed. 
In our study, we showed that GM-CSF treatment alone does not improve blood flow recovery 
after experimental femoral artery occlusion. In our experiments, mice received five 
intraperitoneal injections of rmGM-CSF starting two days before femoral artery ligature. 
After 21 days, LDI measurements only showed a slight increase in blood flow recovery in 
GM-CSF treated mice. However, in contrast to control mice, no necrosis occurred in GM-
CSF treated animals. HOS measurements confirmed that blood flow recovery between GM-
CSF and control mice did not differ. At day 3, HOS of the GM-CSF group was slightly higher 
than in controls, probably because several control mice developed necrosis and had very low 
tissue oxygenation.  
Histological evaluation of the adductor muscles revealed that the mean collateral area in GM-
CSF-treated animals moderately increased compared to controls (1.62 ± 0.06 vs. 1.56 ± 0.07) 
as well as the total collateral area (1.91 ± 0.11 vs. 1.88 ± 0.08). However, these results did not 
reach statistical significance.  
In conclusion, application of GM-CSF alone had a moderate effect on blood flow 
recovery which indicates that GM-CSF has only a supporting role in collateral vessel growth. 
Our results show that application of GM-CSF alone is not suitable for a treatment in the 
mouse ischemic hind limb model. Moreover, higher concentrations of GM-CSF were not well 
tolerated and it was difficult to find a proper concentration that would be effective and not 
toxic. Our data correspond with a study in a rabbit ischemic hind limb model where even local 
intraarterial delivery of GM-CSF did not significantly increase collateral conductance 
(Eitenmueller et al. data not published) but contrast with several previous studies under 
experimental and clinical settings as mentioned before.  
4. Discussion - 67 -
However, pre-treatment with GM-CSF combined with monocyte injections has a synergistic 
effect and accelerates blood flow recovery after experimental femoral artery occlusion. The 
combination of monocyte injections and GM-CSF application allows to use smaller 
concentrations of monocytes with a high effect on blood flow recovery. 
 
4.10. Effect of Cicaprost- and GM-CSF-primed monocytes on blood flow recovery after 
femoral artery ligature 
 
The effect of a stable prostacyclin analogue (Cicaprost) on monocyte incubation has 
not yet been described. We tested, if Cicaprost can enhance their arteriogenic potential. 
Isolated monocytes (2 x 105 cells) were incubated with 100 ng/ml of Cicaprost for two hours 
and than injected into a tail vein of recipients after femoral artery occlusion. 
In summary, LDI and HOS measurements did not support our hypothesis and the results were 
comparable to those from 2 x 105 monocyte-treated mice. In LDI measurements, a slight 
delay of blood flow recovery on day three was detected in mice, which received Cicaprost-
incubated monocytes. However, it was described that Cicaprost decreases TNF-α production 
in activated monocytes 91 and TNF-α is responsible for adhesion and activation of additional 
monocytes. Furthermore, Cicaprost incubation with monocytes may have altered their 
activation status in a way that the transmigration process may have been negatively affected.  
 
The effect of GM-CSF-priming on monocytes was again tested in our mouse ischemic 
hind limb model. GM-CSF is known to have a potent effect in stimulating proliferation, 
maturation and function of hematopoietic cells as well as the ability to enhance the function of 
fully differentiated cells 52. Preliminary studies were performed to determine the optimal dose 
and incubation time for rmGM-CSF in coculture with peritoneal macrophages and the dose 
was established to be 200 ng/ml for two hours 53. 
In our experiment, isolated monocytes (2 x 105 cells) were incubated with 200 ng/ml of 
rmGM-CSF for three hours. Immediately after incubation, cells were injected via a tail vein of 
a recipient after femoral artery ligature. Surprisingly, in two of the recipients a severe necrosis 
developed and they were excluded from the study. Such an incident has never been observed 
in mice treated with monocytes. Blood flow measurements revealed that mice which received 
monocytes incubated with GM-CSF did not show any improvement in comparison to non-
treated animals. Hemoglobin oxygen saturation measurements confirmed these results. 
4. Discussion - 68 -
Morphometrical measurements showed that collateral vessel perimeters did not increase 
compared to controls and the mean collateral vessel area dropped markedly.  
In conclusion, priming of monocytes with GM-CSF may not enhance their arteriogenic 
potential. In contrast, the incubation of monocytes with GM-CSF prior to their injection 
appears to negatively influence arteriogenesis, most likely by decreasing of cytokine 
production. Another possible explanation could be that conditioned monocytes differentiated 
into macrophages and subsequently lost their ability to transmigrate through the vessel wall 
into the collateral area.  
 
4.11. Limitations of arteriogenic therapy 
 
Therapeutic arteriogenesis can be induced via administration of growth factors, cells 
or using artificially increased fluid shear stress 25.  
The efficacy of growth factors, like VEGF, FGF2 and GM-CSF was already proven and/or 
disproven in clinical trials 92, 93, 53. There are often discrepancies in results between animal 
studies and clinical trials. The reasons for this, among other things, may be that in animal 
studies, only young and healthy animals are used and they may show a different response to 
the treatment from the population used in clinical trials, which is mostly represented by 
elderly and polymorbid patients. An age-dependent impairment of collateral vessel 
development was previously reported in animal studies 92. 
Furthermore, for optimal treatment, it is necessary to establish the proper dose and application 
route. On the one hand, systemic administration is often accompanied by several adverse 
events and results in a poor uptake by the targeted tissue. Furthermore, growth factors have 
very short plasma half-lives due to their degradation and binding to endothelial cells 93. On 
the other hand, systemic application is more convenient for the patient and non-invasive. 
Local application as a single bolus may be insufficient and prolonged exposition of the 
growth factor to the targeted tissue is required. With local application of the drug, fewer side 
effects may be achieved. Most of the growth factors are effective only in very high dosages, 
which are close to toxic. There is a need to find an effective combination of growth factors 
instead of using only one. 
We have shown that systemic application of monocytes effectively enhances collateral blood 
flow in the mouse ischemic hind limb model. Systemic application may not be suitable for 
patients with severe atherosclerosis because of a possible pro-atherogenic effect of the 
monocytes due to increased angiogenesis in the vasa vasorum of atherosclerotic plaques 58 55. 
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Transplanted monocytes can as well contribute to impairment of diabetic retinopathy via 
pathological angiogenesis and accumulate in inflammation focuses. 
 
4.12. Lessons from clinical trials on arteriogenesis 
 
Stimulation of coronary arteriogenesis was tested in the VIVA trial 94 using a 
combination of intracoronary and intravenous administration of rhVEGF165 in patients with 
stable exertional angina, unsuitable for standard revascularization. The results did not meet 
the expectations as by day 120 only a high dose of rhVEGF165 (recombinant human vascular 
endothelial growth factor) significantly improved angina class compared to placebo-treated 
patients, and myocardial perfusion imaging measurements with angina frequency evaluations 
only showed non-significant trends.  
In another trial the therapeutic efficacy of rFGF2 (recombinant fibroblast growth factor 2; 
FIRST trial) was tested by single-bolus intracoronary infusion over 10 minutes 95. By day 90, 
exercise tolerance tests did not show any significant differences between FGF2- and placebo-
treated patients as well as SPECT (single photon emission computed tomography) myocardial 
perfusion measurements. But the angina frequency score was significantly reduced in FGF2-
treated patients. Possible explanations for these results are suboptimal dose or exposure time 
of applicated FGF2 growth factor and decreased therapy response in elderly patients or no 
arteriogenic functions of FGF2.  
Therapeutic arteriogenesis in patients with peripheral artery disease was solely tested in the 
TRAFFIC trial 96 using intra-arterial administration of rhFGF2 in patients with inguinal 
atherosclerosis. The results showed significant improvement in the peak walking time on day 
90 in patients treated with a single dose of rhFGF2 compared to those treated with placebo. 
Controversially, patients which received a double dose of rhFGF2 showed no significant 
improvement in the peak walking time compared to the placebo group. The study may have 
suffered from the lack of direct parameters like collateral conductance values.  
Therapeutic implications of rhGM-CSF (recombinant human granulocyte-macrophage 
colony-stimulating actor; Molgramostim) was tested in patients with severe coronary artery 
disease which were unable to undergo coronary artery bypass surgery 55. Patients received an 
intracoronary injection of 40 µg of GM-CSF or placebo followed by a subcutaneous 
administration of GM-CSF (10µg/kg) or placebo for two weeks. Collateral flow index (CFI) 
was measured after experimental PTCA occlusion for one minute. CFI in placebo-treated 
patients decreased but increased in GM-CSF-treated patients compared to pre- treatment 
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measurements after two week observation period. The difference between pre- and post-
treatment CFI values was significant in the GM-CSF treated group of patients. However, the 
study was extensively criticized 97 because of methodological problems. The comments were 
concerning the relevancy of the short study time period (two weeks) and high intrinsic 
variability of the applied method for CFI measurements.  
No clinical trial using GM-CSF in the treatment of peripheral occlusive disease has yet been 
performed. 
There are several possibilities of explanation why previously described clinical trials 
did not meet the expectations. Results from animal studies suggest that the application of a 
single growth factor does not completely restore physiological blood. There is a need to find a 
combination of growth factors which allows to use lower doses and avoids the adverse events. 
Finally, as mentioned before, application route has to be chosen based on the hypothesized 
mechanism by which the tested substance could stimulate arteriogenesis. The consideration, 
which have to be done prior to a clinical approach can be summarized as followed: The right 
factor has to be at the right place at the right time in order to be supportive. 
 
4.13. Conclusions 
 
In conclusion, we showed that infusion of monocytes enhances blood flow recovery in 
the ischemic leg after experimental occlusion of the femoral artery. This improvement was 
related to the concentration of injected monocytes. Moreover, the combination of GM-CSF 
and monocyte treatment had an additive effect and resulted in superior blood flow recovery 
and well developed collaterals. Our results indicate that GM-CSF only has a supporting role 
in arteriogenesis and treatment with GM-CSF alone does not have the ability to improve 
blood flow recovery after arterial occlusions.  
Finally, we found that priming of monocytes with Cicaprost or GM-CSF prior to injection 
does not support arteriogenesis, most likely because the migration process of these cells was 
negatively influenced.  
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5. Abbreviations 
 
°C degrees Centigrade 
µg microgram 
µl microliter 
µm² square micrometer 
A. arteria 
BS1 lectin bandeiraea simplicifolia 1 lectin 
BSA bovine serum albumin 
CCR-2 CC-chemokine receptor-2 
COX cyclooxygenase 
DAPI 4’,6-diamino-2-phenylindole dilactate 
EPC endothelial progenitor cells 
FGF fibroblast growth factor 
Fig. figure 
FITC fluorescein-5-isothyocyanate 
FSS fluid shear stress 
g acceleration due to gravity 
g gram 
GFP green fluorescent protein 
GM-CSF granulocyte-macrophage colony-stimulating factor 
h hour 
HCl hydrochloric acid 
HIF hypoxia inducible transription factor 
HOS hemoglobin oxygen saturation 
Hz hertz 
i.p. intraperitoneal 
I.U. international units 
i.v. intravenous 
ICAM intercellular cell adhesion molecule 
IFN-γ interferon-gamma 
IL interleukin 
kd kilodalton 
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kHz kilohertz 
kV kilovolt 
L liter 
LDI Laser Doppler Imaging 
mA milliampere 
MCP-1 monocyte chemoattractant protein-1 
M-CSF macrophage colony-stimulating factor 
mg milligram 
min minute 
ml milliliter 
MMP matrix metalloprotease 
ms millisecond 
N number of animals 
N. nervus 
NaCl sodium chloride 
ng nanogram 
NO nitric oxide 
PBS phosphate-buffered saline 
PDGF platelet-derived growth factor 
PE phycoerithrin 
pFA paraformaldehyde 
PlGF placental growth factor 
psi pounds per square inch 
rh recombinant human 
rm recombinant murine 
rpm rounds per minute 
s.c. subcutaneous 
SEM standard error of the mean 
SMC smooth muscle cells 
Tab. table 
TGF-β transforming growth factor-beta 
TNF-α tumour necrosis factor-alpha 
t-PA tissue-plasminogen activator 
TRITC tetramethylrhodamine isothiocyanate 
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u-PA urokinase-plasminogen activator 
V. vena 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
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7. Summary 
 
Arteriogenesis, the growth of collateral arteries as a compensatory mechanism after 
occlusion of a major artery, is a complex process in which peripheral blood cells have been 
proposed to be involved. This study was concentrated on the role of monocytes, effects of 
different monocyte concentrations in the blood and effects of monocyte pre-treatment with 
specific substances on the enhancement of collateral artery growth. 
For this purpose, a mouse ischemic hind limb model was established on the BALB/c 
genetic background. After acute femoral artery occlusion, mice received intravenous 
injections of monocytes in several concentrations, isolated from donor littermates using a cell 
sorter. Moreover, we pre-treated monocytes with a synthetic prostaglandin (Cicaprost) or with 
granulocyte-macrophage colony-stimulating factor (GM-CSF). We also evaluated if treatment 
of operated mice with GM-CSF alone could enhance collateral artery growth and if a 
combination of monocyte injections with GM-CSF had a synergistic effect. Pedal blood flow 
recovery in mice was measured using the laser Doppler imaging technique immediately after 
operation and on postoperative day 3, 7, 14 and 21. Moreover, pedal hemoglobin oxygen 
saturation was estimated at the same time points. Functional recovery of the foot movement 
was observed during the whole trial period. On the day 21 after the operation, post-mortem 
angiogramms were performed and adductor muscles were harvested for the morphometrical 
analysis.  
The hemodynamic data showed that injection of monocytes had a concentration-
dependent effect in enhancing of blood flow recovery in the operated foot. Seven days after 
femoral artery ligature, the blood flow recovery (right-to-left ratio) was only 0.21 ± 0.02 in 
control mice and significantly higher in mice which had obtained monocyte injections (0.30 ± 
0.04 in mice with 2x105 monocytes injected, p<0.05 and 0.33 ± 0.04 in mice with 3x105 
monocytes injected, p<0.01). Morphometrical analysis of adductor muscles of operated and 
non-operated hind limbs showed that total collateral area ratio, which was obtained as a 
parameter to estimate collateral artery size, increased markedly in monocyte-treated mice 
compared to controls (2.37 ± 0.12 in mice with 2x105 monocytes injected; p<0.01 and 2.66 ± 
0.12 in mice with 3x105 monocytes injected; p<0.01 vs. 1.88 ± 0.08 in controls). Pre-
treatment of monocytes with Cicaprost or GM-CSF did not enhance their arteriogenic 
properties. Administration of GM-CSF via intraperitoneal injections did not enhance the 
blood flow recovery, however the combination of GM-CSF and monocyte injections had a 
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moderate synergistic effect reflected in blood flow measurements (R/L ratio on day 7 was 
0.40 ± 0.05 which was the highest ratio of all experimental groups of animals; p<0.01), as 
well as in morphometrical analysis of adductor muscles (total collateral area ratio was 3.32 ± 
0.14; p<0.01)  
Our results show that monocytes/macrophages play a crucial role in enhancement of 
collateral artery growth. In addition, a combination of GM-CSF treatment and monocyte 
injections allows administration of smaller concentrations of therapeutics and results in a 
superior blood flow recovery. Our study suggests a possibility of using cellular approaches for 
the treatment of vascular occlusive diseases. 
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8. Zusammenfassung 
 
Als Arteriogenese wird das kompensatorische Wachstum von Kollateralgefäßen nach 
arteriellen Verschlüssen bzw. chronischen Stenosen bezeichnet. Aufgrund von Ergebnissen 
frühere Studien vermutete man, dass an den komplexen Prozessen, die dieses Wachstum 
charakterisieren, zirkulierende Blutzellen, vor allem Leukozyten, beteiligt sind. Zielsetzung 
dieser Studie war es deshalb, die Rolle der Monozyten, die Effekte unterschiedlicher 
Blutmonozytenkonzentrationen und den Einfluss einer Vorbehandlung der Monozyten mit 
spezifischen Substanzen auf die Arteriogenese zu untersuchen. 
Hiezu wurde das Hinterlauf-Ischämien-Modell in der Maus (BALB/c) verwendet. 
Nach dem Verschluss der Arteria femoralis erhielten die Mäuse in unterschiedlichen 
Konzentrationen intravenöse Injektionen von Monozyten, die zuvor aus genetisch identischen 
Mäusen mittels cell sorter isoliert wurden. Weitere Versuchsgruppen wurden mit Monozyten 
behandelt, die zuvor mit einem synthetischen Prostaglandinen (Cicaprost) bzw. mit dem 
Granulozyten-Makrophagen-Kolonie-stimulierenden Faktor (GM-CSF) vorbehandelt wurden. 
Es wurde ebenfalls untersucht, ob Injektionen von GM-CSF das Kollateralgefäßwachstum 
nach Okklusion der Femoralarterie verstärken und ob eine Kombinationstherapie aus GM-
CSF-Injektionen und Monozytentransplantationen einen zusätzlichen stimulativen Effekt 
haben. Sofort nach der Operation als auch an den Tagen 3, 7, 14 und 21 wurden Laserdoppler-
Untersuchungen zur Bestimmung der Wiederherstellung der pedalen Durchblutung 
durchgeführt. Zusätzlich wurde die Sauerstoff-Sättigung im Hämoglobin in den distalen 
Gefäßen bestimmt. Als funktioneller Parameter während des Beobachtungszeitraumes wurde 
die aktive Bewegung der Hinterläufe quantifiziert. Drei Wochen nach Versuchsbeginn wurde 
das Kollateralgefäßsystem durch Angiographien post mortem dargestellt und Gewebeproben 
zur morphometrischen Analyse konserviert. 
Die hämodynamischen Daten zeigen, dass die Monozyteninjektionen einen 
dosisabhängigen positiven Effekt auf das Kollateralgefäßwachstum hatten. Am siebten Tag 
nach dem Verschluss der Arteria femoralis war der pedale Blutfluss (rechts-zu-links Rate) in 
Kontrollmäusen nur 0,21 ± 0,02 und signifikant höher in Mäusen, die Monozyten injiziert 
bekommen haben (0,30 ± 0,04 in Mäusen, die 2x105 Monozyten bekommen haben; p<0,05 
und 0,33 ± 0,04 in Mäusen, die 3x105 Monozyten bekommen haben; p<0,01). 
Morphometrische Analysen der Adduktoren von den operierten und nicht operierten 
Hinterläufen ergaben, dass die gesamte Kollateralflächenrate, die als Parameter zur 
Bewertung der Kollateralgefäßgröße diente, war in Monozyten behandelten Mäusen 
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verglichen mit den Kontrollen deutlich erhöht (2,37 ± 0,12 in Mäusen, die 2x105 Monozyten 
bekommen haben; p<0,01 und 2,66 ± 0,12 in Mäusen, die 3x105 Monozyten bekommen 
haben; p<0,01 vs. 1,88 ± 0,08 in Kontrollen). In Gegensatz hierzu hatten die 
Vorbehandlungen der Monozyten mit Cicaprost oder GM-CSF keinen weiteren arteriogenen 
Effekt. Des weiteren verstärkten die Injektionen von GM-CSF die Wiederherstellung der 
Durchblutung nicht, auch wenn die Kombinationstherapie von GM-CSF und Monozyten-
Injektionen einen moderaten synergistischen Effekt hatte (R/L Rate am Tag 7 war 0,40 ± 
0,05, der höchste Wert von allen Versuchsgruppen; p<0,01). Diese Ergebnisse wurden durch 
histologische Untersuchungen der Adduktorenmuskulatur von operierten und nicht operierten 
Hinterläufen erhärtet (die gesamte Kollateralflächenrate war 3,32 ± 0,14; p<0,01). 
Die Ergebnisse zeigen, dass die Monozyten/Makrophagen eine wichtige Rolle in der 
Stimulierung des Kollateralgefäßwachstums spielen. Außerdem ist es möglich durch die 
Kombination von GM-CSF- mit Monozyten-Injektionen die Konzentrationen der 
Therapeutika gegenüber der Einzeldosierungen zu reduzieren, wobei trotzdem die besten 
Ergebnisse erzielt werden konnten. In dieser Studie wurden die Grundlagen zum Einsatz 
zellulärer Therapeutika in der Behandlung von Herz-Kreislauf-Erkrankungen geschaffen.  
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